Document:

exv10w2

EXHIBIT 10.2

VOTING AND EXCHANGE TRUST AGREEMENT

THIS AGREEMENT is made the 24th day of July, 2008,

B E T W E E N:

NORTH AMERICAN NATURAL GAS, INC., a corporation existing under the laws of the State
of Washington,

(hereinafter referred to as “PureRay U.S.”),

- and -

PURERAY HOLDINGS ULC, an unlimited liability corporation formed under the laws of
the Province of Alberta,

(hereinafter referred to as “PureRay Holdings”),

- and -

PURERAY ACQUISITION INC., a corporation formed under the laws of Canada,

(hereinafter referred to as the “Corporation”),

- and -

DEREK BLACKBURN, an individual resident in the Village of Manotick, in the Province
of Ontario,

(hereinafter referred to as “Trustee”)

WHEREAS:

	A.	 	the Corporation is a wholly-owned subsidiary of PureRay Holdings and PureRay Holdings is a
wholly-owned subsidiary of PureRay U.S.;
	 
	B.	 	pursuant to a share purchase agreement dated July 24, 2008 (the “Purchase Agreement”),
between PureRay U.S., PureRay Holdings, the Corporation and all of the shareholders of PureRay
Corporation (“PureRay”), the Corporation has agreed to acquire all of the outstanding shares
in the capital of PureRay and, in satisfaction of payment of the purchase price therefor, to
issue one Exchangeable Shares (as hereinafter defined) for each such share of PureRay acquired
by the Corporation;
	 
	C.	 	PureRay Holdings is to grant to and in favour of each holder of Exchangeable Shares (as
hereinafter defined) the right to require PureRay Holdings to purchase from such holder all or
any

 

 

 - 2 -

	 	 	part of the Exchangeable Shares (as hereinafter defined) held by such holder on the terms
and conditions set forth in this Agreement; and
	 
	D.	 	the parties desire to make appropriate provisions and to establish a procedure whereby the
rights to require PureRay to purchase Exchangeable Shares (as hereinafter defined) from the
holders thereto shall be exercisable by such holders from time to time;

NOW THEREFORE, in consideration of the respective covenants provided in this Agreement and for
other good and valuable consideration (the receipt and sufficiency of which are hereby
acknowledged), the parties agree as follows:

ARTICLE 1

DEFINITIONS AND INTERPRETATION

1.1 Definitions

In this Agreement, the following terms shall have the following meanings:

	 	 	“Affiliate” of any person means any other person directly or indirectly controlled by, or
under control of, that person. For the purposes of this definition, “control” (including,
with correlative meanings, the terms “controlled by” and “under common control of”), as
applied to any person, means the possession by another person, directly or indirectly, of
the power to direct or cause the direction of the management and policies of that first
mentioned person, whether through the ownership of voting securities, by contract or
otherwise.
	 
	 	 	“Automatic Exchange Rights” means the benefit of the obligation of PureRay Holdings to
effect the automatic exchange of PureRay U.S. Common Shares for Exchangeable Shares pursuant
to section 5.11.
	 
	 	 	“Beneficiaries” means the registered holders from time to time of Exchangeable Shares, other
than PureRay U.S. and its Affiliates.
	 
	 	 	“Beneficiary Votes” has the meaning ascribed thereto in section 4.2.
	 
	 	 	“Board of Directors” means the board of directors of the Corporation.
	 
	 	 	“Business Day” means any day on which commercial banks are open for business in Toronto,
Ontario, other than a Saturday, a Sunday or a day observed as a holiday in Toronto, Ontario
under the laws of the province of Ontario or the federal laws of Canada.
	 
	 	 	“Canadian Dollar Equivalent” means, in respect of an amount expressed in a currency other
than Canadian dollars (the “Foreign Currency Amount”) at any date, the product obtained by
multiplying: (i) the Foreign Currency Amount by (ii) the noon spot exchange rate on such
date for such foreign currency expressed in Canadian dollars as reported by the Bank of
Canada or, in the event such spot exchange rate is not available, such exchange rate on such
date for such foreign currency expressed in Canadian dollars as may be deemed by the Board
of Directors to be appropriate for such purpose.
	 
	 	 	“Current Market Price” means, in respect of a PureRay U.S. Common Share on any date, the
Canadian Dollar Equivalent of the average of the closing bid and asked prices of PureRay
U.S. Common Shares during a period of 20 consecutive trading days ending not more than three

 

- 3 -

	 	 	trading days before such date on such stock exchange or automated quotation system on which
the PureRay U.S. Common Shares are listed or quoted, as the case may be, as may be selected
by the Board of Directors for such purpose; provided however, that if the PureRay U.S.
Common Shares are not then quoted on any stock exchange or automated quotation system or if,
in the opinion of the Board of Directors, the public distribution or trading activity of
PureRay U.S. Common Shares during such period does not create a market which reflects the
fair market value of a PureRay U.S. Common Share, then the Current Market Price of a PureRay
U.S. Common Share shall be determined by the Board of Directors, in good faith and in its
sole discretion, and provided further that any such selection, opinion or determination by
the Board of Directors shall be conclusive and binding.
	 
	 	 	“Exchange Right” has the meaning ascribed thereto in section 5.l.
	 
	 	 	“Exchangeable Shares” means the non-voting exchangeable shares in the capital of the
Corporation.
	 
	 	 	“Insolvency Event” means the institution by the Corporation of any proceeding to be
adjudicated a bankrupt or insolvent or to be wound up, or the consent of the Corporation to
the institution of bankruptcy, insolvency or winding-up proceedings against it, or the
filing of a petition, answer or consent seeking dissolution or winding-up under any
bankruptcy, insolvency or analogous laws, including without limitation the Companies
Creditors’ Arrangement Act (Canada) and the Bankruptcy and Insolvency Act (Canada), and the
failure by the Corporation to contest in good faith any such proceedings commenced in
respect of the Corporation within 30 days of becoming aware thereof, or the consent by the
Corporation to the filing of any such petition or to the appointment of a receiver, or the
making by the Corporation of a general assignment for the benefit of creditors, or the
admission in writing by the Corporation of its inability to pay its debts generally as they
become due, or the Corporation not being permitted, pursuant to solvency requirements of
applicable law, to redeem any Retracted Shares pursuant to section 5.7 of the Share
Provisions.
	 
	 	 	“ITA” means the Income Tax Act (Canada), as amended.
	 
	 	 	“Liquidation Call Right” has the meaning ascribed thereto in the Share Provisions.
	 
	 	 	“Liquidation Event” has the meaning ascribed thereto in section 5.11(b).
	 
	 	 	“Liquidation Event Effective Date” has the meaning ascribed thereto in section 5.11(c).
	 
	 	 	“List” has the meaning ascribed thereto in section 4.6.
	 
	 	 	“Officer’s Certificate” means, with respect to PureRay U.S. or the Corporation, as the case
may be, a certificate signed by any one officer or director of PureRay U.S. or the
Corporation, as the case may be.
	 
	 	 	“Person” includes an individual, partnership, corporation, company, unincorporated syndicate
or organization, trust, trustee, executor, administrator and other legal representative.
	 
	 	 	“PureRay U.S. Affiliates” means Affiliates of PureRay U.S.
	 
	 	 	“PureRay U.S. Common Share” means an authorized share of common stock, par value U.S.
$0.0001, in the capital of PureRay U.S.

 

- 4 -

	 	 	“PureRay U.S. Consent” has the meaning ascribed thereto in section 4.2.
	 
	 	 	“PureRay U.S. Meeting” has the meaning ascribed thereto in section 4.2.
	 
	 	 	“PureRay U.S. Special Voting Share” means an authorized share of Special Voting Stock of
PureRay U.S., par value U.S.$0.0001, which entitles the holder of record to four votes in
respect of each such share and one vote in respect of each one-quarter of a share, all of
which shares are to be issued to, deposited with, and voted by, the Trustee as described
herein.
	 
	 	 	“PureRay U.S. Successor” has the meaning ascribed thereto in section 11.1 (a).
	 
	 	 	“Redemption Call Right” has the meaning ascribed thereto in the Share Provisions.
	 
	 	 	“Remittance Date” has the meaning ascribed thereto in the Share Provisions.
	 
	 	 	“Retracted Shares” has the meaning ascribed thereto in section 5.7.
	 
	 	 	“Retraction Call Right” has the meaning ascribed thereto in the Share Provisions.
	 
	 	 	“Share Provisions” means the rights, privileges, restrictions and conditions attaching to
the Exchangeable Shares.
	 
	 	 	“Support Agreement” means the support agreement made as of even date herewith between
PureRay U.S., PureRay Holdings and the Corporation.
	 
	 	 	“Trust” means the trust created by this Agreement.
	 
	 	 	“Trust Estate” means the PureRay U.S. Special Voting Shares, any other securities, the
Exchange Right, the Automatic Exchange Rights and any money or other property which may be
held by the Trustee from time to time pursuant to this trust agreement.
	 
	 	 	“Voting Rights” means the voting rights attached to the PureRay U.S. Special Voting Shares.

1.2 Interpretation Not Affected by Headings, etc.

The division of this Agreement into Articles, sections and other portions and the insertion of
headings are for convenience of reference only and should not affect the construction or
interpretation of this Agreement. Unless otherwise indicated, all references to an “Article” or
“section” followed by a number and/or a letter refer to the specified Article or section of this
Agreement. The terms “this Agreement”, “hereof”, “herein” and “hereunder” and similar expressions
refer to this Agreement and not to any particular Article, section or other portion hereof and
include any agreement or instrument supplementary or ancillary hereto.

1.3 Number, Gender, etc.

Words importing the singular number only shall include the plural and vice versa. Words importing
any gender shall include the feminine and the masculine.

1.4 Date for any Action

 

- 5 -

If any date on which any action is required to be taken under this Agreement is not a Business Day,
such action shall be required to be taken on the next succeeding Business Day.

ARTICLE 2

PURPOSE OF AGREEMENT

2.1 Establishment of Trust

The purpose of this Agreement is to create the Trust for the benefit of the Beneficiaries, as
herein provided. The Trustee will hold the PureRay U.S. Special Voting Shares in order to enable
the Trustee to exercise the Voting Rights and will hold the Exchange Rights and the Automatic
Exchange Rights in order to enable the Trustee to exercise such rights, in each case as trustee for
and on behalf of the Beneficiaries as provided in this Agreement.

ARTICLE 3

PURERAY U.S. SPECIAL VOTING SHARES

3.1 Issue and Ownership of the PureRay U.S. Special Voting Shares

PureRay U.S. hereby issues to and deposits with the Trustee, 8,963,750 PureRay U.S. Special Voting
Shares to be hereafter held of record by the Trustee as trustee for and on behalf of, and for the
use and benefit of, the Beneficiaries and in accordance with the provisions of this Agreement.
PureRay U.S. hereby acknowledges receipt from the Trustee as trustee for and on behalf of the
Beneficiaries of good and valuable consideration (and the adequacy thereof) for the issuance of the
PureRay U.S. Special Voting Shares by PureRay U.S. to the Trustee. During the term of the Trust
and subject to the terms and conditions of this Agreement, the Trustee shall possess and be vested
with full legal ownership of the PureRay U.S. Special Voting Shares and shall be entitled to
exercise all of the rights and powers of an owner with respect to the PureRay U.S. Special Voting
Shares provided that the Trustee shall:

	 	(a)	 	hold the PureRay U.S. Special Voting Shares and the legal title thereto as
trustee solely for the use and benefit of the Beneficiaries in accordance with the
provisions of this Agreement; and
	 
	 	(b)	 	except as specifically authorized by this Agreement, have no power or authority
to sell, transfer, vote or otherwise deal in or with the PureRay U.S. Special Voting
Shares and the PureRay U.S. Special Voting Shares shall not be used or disposed of by
the Trustee for any purpose other than the purposes for which this Trust is created
pursuant to this Agreement.

3.2 Legended Share Certificates

The Corporation will cause each certificate representing Exchangeable Shares to bear an appropriate
legend notifying the Beneficiaries of their right to instruct the Trustee with respect to the
exercise of the Voting Rights in respect of the Exchangeable Shares of the Beneficiaries.

3.3 Safe Keeping of Certificate

The certificate(s) representing the PureRay U.S. Special Voting Shares shall at all times be held
in safe keeping by the Trustee.

 

- 6 -

ARTICLE 4

EXERCISE OF VOTING RIGHTS

4.1 Voting Rights

The Trustee, as the holder of record of the PureRay U.S. Special Voting Shares, shall be entitled
to all of the Voting Rights, including the right to vote in person or by proxy the PureRay U.S.
Special Voting Shares on any matters, questions, proposals or propositions whatsoever that may
properly come before the shareholders of PureRay U.S. at a PureRay U.S. Meeting or in connection
with a PureRay U.S. Consent. The Voting Rights shall be and remain vested in and exercised by the
Trustee. Subject to section 7.14:

	 	(a)	 	the Trustee shall exercise the Voting Rights only on the basis of instructions
received pursuant to this Article 4 from Beneficiaries entitled to instruct the Trustee
as to the voting thereof at the time at which the PureRay U.S. Meeting is held; and
	 
	 	(b)	 	to the extent that no instructions are received from a Beneficiary with respect
to the Voting Rights to which such Beneficiary is entitled, the Trustee shall not
exercise or permit the exercise of such Voting Rights.

4.2 Number of Votes

With respect to all meetings of shareholders of PureRay U.S. at which holders of PureRay U.S.
Common Shares are entitled to vote (each, a “PureRay U.S. Meeting”) and with respect to all written
consents sought by PureRay U.S. from its shareholders including the holders of PureRay U.S. Common
Shares (each, a “PureRay U.S. Consent”), each Beneficiary shall be entitled to instruct the Trustee
to cast and exercise one of the votes comprised in the Voting Rights for each Exchangeable Share
owned of record by such Beneficiary on the record date established by PureRay U.S. or by applicable
law for such PureRay U.S. Meeting or PureRay U.S. Consent, as the case may be (the “Beneficiary
Votes”), in respect of each matter, question, proposal or proposition to be voted on at such
PureRay U.S. Meeting or in connection with such PureRay U.S. Consent.

4.3 Mailings to Shareholders

With respect to each PureRay U.S. Meeting and PureRay U.S. Consent, PureRay U.S. will mail (or
otherwise communicate in the same manner as PureRay U.S. utilizes in communications to holders of
PureRay U.S. Common Shares) to the Trustee and each of the Beneficiaries named in the List referred
to in section 4.6, such mailing or communication to commence on the same day as the mailing or
notice (or other communication) with respect thereto is commenced by PureRay U.S. to its
shareholders:

	 	(a)	 	a copy of such notice, together with any related materials to be provided to
shareholders of PureRay U.S.;
	 
	 	(b)	 	a statement that such Beneficiary is entitled to instruct the Trustee as to the
exercise of the Beneficiary Votes with respect to such PureRay U.S. Meeting or PureRay
U.S. Consent or, pursuant to section 4.7, to attend such PureRay U.S. Meeting and to
exercise personally the Beneficiary Votes thereat;
	 
	 	(c)	 	a statement as to the manner in which such instructions may be given to the
Trustee, including an express indication that instructions may be given to the Trustee
to give:

	 	(i)	 	a proxy to such Beneficiary or his designee to exercise
personally the Beneficiary

 

- 7 -

	 	 	 	Votes; or
	 
	 	(ii)	 	a proxy to a designated agent or other representative of the
management of PureRay U.S. to exercise such Beneficiary Votes;

	 	(d)	 	a statement that if no such instructions are received from the Beneficiary, the
Beneficiary Votes to which such Beneficiary is entitled will not be exercised;
	 
	 	(e)	 	a form of direction whereby the Beneficiary may so direct and instruct the
Trustee as contemplated herein; and
	 
	 	(f)	 	a statement of the time and date by which such instructions must be received by
the Trustee in order to be binding upon it, which in the case of a PureRay U.S. Meeting
shall not be earlier than the close of business on the second Business Day before such
meeting, and of the method for revoking or amending such instructions. For the purpose
of determining Beneficiary Votes to which a Beneficiary is entitled in respect of any
PureRay U.S. Meeting or PureRay U.S. Consent, the number of Exchangeable Shares owned
of record by the Beneficiary shall be determined at the close of business on the record
date established by PureRay U.S. or by applicable law for purposes of determining
shareholders entitled to vote at such PureRay U.S. Meeting.

PureRay U.S. will notify the Trustee of any decision of the board of directors of PureRay U.S. with
respect to the calling of any PureRay U.S. Meeting and shall provide all necessary information and
materials to the Trustee in each case promptly and in any event in sufficient time to enable the
Trustee to perform its obligations contemplated by this section 4.3.

4.4 Copies of Shareholder Information

PureRay U.S. will deliver to the Trustee and each Beneficiary, at the same time as such materials
are first sent to holders of PureRay U.S. Common Shares, all proxy materials (including notices of
PureRay U.S. Meetings but excluding proxies to vote PureRay U.S. Common Shares), information
statements, reports (including without limitation, all interim and annual financial statements) and
other written communications that, in each case, are to be distributed from time to time to holders
of PureRay U.S. Common Shares (and all materials specifically directed to the Beneficiaries or to
the Trustee for the benefit of the Beneficiaries by PureRay U.S.).

4.5 Other Materials

As soon as reasonably practicable after receipt by PureRay U.S. or shareholders of PureRay U.S. (if
such receipt is known by PureRay U.S.) of any material sent or given by or on behalf of a third
party to holders of PureRay U.S. Common Shares generally, including without limitation, dissident
proxy and information circulars (and related information and material) and tender and exchange
offer circulars (and related information and material), PureRay U.S. shall use its reasonable
efforts to obtain and deliver to the Trustee and each Beneficiary copies thereof (unless the same
has been provided directly to the Trustee and Beneficiaries by such third party).

 

- 8 -

4.6 List of Persons Entitled to Vote

The Corporation shall:

	 	(a)	 	before each annual, general and special PureRay U.S. Meeting or the seeking of
any PureRay U.S. Consent; and
	 
	 	(b)	 	forthwith upon each request made at any time by the Trustee or PureRay U.S. in
writing,

prepare or cause to be prepared a list (a “List”) of the names and addresses of the Beneficiaries
arranged in alphabetical order and showing the number of Exchangeable Shares held of record by each
such Beneficiary, in each case at the close of business on the date specified by the Trustee or
PureRay U.S., as applicable, in such request or, in the case of a List prepared in connection with
a PureRay U.S. Meeting or a PureRay U.S. Consent, at the close of business on the record date
established by PureRay U.S. or pursuant to applicable law for determining the holders of PureRay
U.S. Common Shares entitled to receive notice of and/or to vote at such PureRay U.S. Meeting or to
give consent in connection with such PureRay U.S. Consent. Each such List shall be delivered to
the Trustee or PureRay U.S., as applicable, promptly after receipt by the Corporation of such
request or the record date for such meeting or seeking of consent, as the case may be. PureRay
U.S. agrees to give the Corporation notice (with a copy to the Trustee) of the calling of any
PureRay U.S. Meeting or the seeking of any PureRay U.S. Consent, together with the record dates
therefor, sufficiently before the date of the calling of such meeting or seeking of such consent so
as to enable the Corporation to perform its obligations under this section 4.6.

4.7 Entitlement to Direct Votes

Any Beneficiary named in a List prepared in connection with any PureRay U.S. Meeting or PureRay
U.S. Consent will be entitle: (i) to instruct the Trustee in the manner described in section 4.3
with respect to the exercise of the Beneficiary Votes to which such Beneficiary is entitled, or
(ii) to attend such meeting and personally exercise thereat, as the proxy of the Trustee, the
Beneficiary Votes to which such Beneficiary is entitled.

4.8 Voting by Trustee, and Attendance of Trustee Representative at Meeting

	(a)	 	In connection with each PureRay U.S. Meeting and PureRay U.S. Consent, the Trustee shall
exercise, either in person or by proxy, in accordance with the instructions received from a
Beneficiary pursuant to section 4.3, the Beneficiary Votes as to which such Beneficiary is
entitled to direct the vote (or any lesser number thereof as may be set forth in the
instructions); provided, however, that such written instructions are received by the Trustee
from the Beneficiary before the time and date fixed by PureRay U.S. for receipt of such
instruction in the notice given by PureRay U.S. to the Beneficiary pursuant to section 4.3.
	 
	(b)	 	The Trustee shall, or shall cause a representative who is empowered to sign and deliver on
behalf of the Trustee, proxies for Voting Rights to attend each PureRay U.S. Meeting. Upon
submission by a Beneficiary (or its designee) of identification satisfactory to the Trustee or
the Trustee’s representative, and at the Beneficiary’s request, the Trustee or such
representative shall sign and deliver to such Beneficiary (or its designee) a proxy to
exercise personally the Beneficiary Votes as to which such Beneficiary is otherwise entitled
hereunder to direct the vote, if such Beneficiary either: (i) has not previously given the
Trustee instructions pursuant to section 4.3 in respect of such meeting, or (ii) submits to
such representative written revocation of any such previous instructions. At such meeting,
the Beneficiary exercising such Beneficiary Votes shall have the same rights as the Trustee to
speak at the meeting in favour of any matter, question, proposal or

 

- 9 -

	 	 	proposition, to vote by way of ballot at the meeting in respect of any matter, question,
proposal or proposition, and to vote at such meeting by way of a show of hands in respect of
any matter, question or proposition.

4.9 Distribution of Written Materials

Any written materials distributed by PureRay U.S. pursuant to this Agreement shall be sent by mail
(or otherwise communicated in the same manner as PureRay U.S. utilizes in communications to holders
of PureRay U.S. Common Shares) to each Beneficiary at its address as shown on the books of the
Corporation and to the Trustee at its address set out in section 14.3 hereof.

4.10 Termination of Voting Rights

All of the rights of a Beneficiary with respect to the Beneficiary Votes exercisable in respect of
the Exchangeable Shares held by such Beneficiary, including the right to instruct the Trustee as to
the voting of or to vote personally such Beneficiary Votes, shall be deemed to be surrendered by
the Beneficiary to the Corporation or PureRay Holdings, as the case may be, and such Beneficiary
Votes and the Voting Rights represented thereby shall cease immediately upon the delivery by such
holder to the Trustee of the certificates representing such Exchangeable Shares in connection with
the exercise by the Beneficiary of the Exchange Right or the occurrence of the automatic exchange
of Exchangeable Shares for PureRay U.S. Common Shares, as specified in Article 5 (unless, in either
case, PureRay U.S. shall not have delivered the requisite PureRay U.S. Common Shares issuable in
exchange therefor to the Trustee for delivery to the Beneficiaries), or upon the redemption of
Exchangeable Shares pursuant to section 5 or 6 of the Share Provisions, or upon the effective date
of the liquidation, dissolution or winding-up of the Corporation pursuant to section 4 of the Share
Provisions, or upon the purchase of Exchangeable Shares from the holder thereof by PureRay Holdings
pursuant to the exercise by PureRay Holdings of the Retraction Call Right, the Redemption Call
Right or the Liquidation Call Right.

ARTICLE 5

EXCHANGE RIGHT AND AUTOMATIC EXCHANGE

5.1 Grant and Ownership of the Exchange Right

PureRay Holdings hereby grants to the Trustee as trustee for and on behalf of, and for the use and
benefit of, the Beneficiaries: (i) the right (the “Exchange Right”), upon the occurrence and during
the continuance of an Insolvency Event, to require PureRay Holdings to purchase from each or any
Beneficiary all or any part of the Exchangeable Shares held by the Beneficiary; and (ii) the
Automatic Exchange Rights, all in accordance with the provisions of this Agreement. PureRay
Holdings hereby acknowledges receipt from the Trustee as trustee for and on behalf of the
Beneficiaries of good and valuable consideration (and the adequacy thereof) for the grant of the
Exchange Right and the Automatic Exchange Rights by PureRay Holdings to the Trustee. During the
term of the Trust and subject to the terms and conditions of this Agreement, the Trustee shall
possess and be vested with full legal ownership of the Exchange Right and the Automatic Exchange
Rights and shall be entitled to exercise all of the rights and powers of an owner with respect to
the Exchange Right and the Automatic Exchange Rights, provided that the Trustee shall:

	 	(a)	 	hold the Exchange Right and the Automatic Exchange Rights and the legal title
thereto as trustee solely for the use and benefit of the Beneficiaries in accordance
with the provisions of this Agreement; and

 

- 10 -

	 	(b)	 	except as specifically authorized by this Agreement, have no power or authority
to exercise or otherwise deal in or with the Exchange Right or the Automatic Exchange
Rights, and the Trustee shall not exercise any such rights for any purpose other than
the purposes for which the Trust is created pursuant to this Agreement.

5.2 Legended Share Certificates

The Corporation will cause each certificate representing Exchangeable Shares to bear an appropriate
legend notifying the Beneficiaries of:

	 	(a)	 	their right to instruct the Trustee with respect to the exercise of the
Exchange Right in respect of the Exchangeable Shares held by a Beneficiary; and
	 
	 	(b)	 	the Automatic Exchange Rights.

5.3 General Exercise of Exchange Right

The Exchange Right shall be and remain vested in and exercisable by the Trustee. Subject to
section 7.14, the Trustee shall exercise the Exchange Right only on the basis of instructions
received pursuant to this Article 5 from Beneficiaries entitled to instruct the Trustee as to the
exercise thereof. To the extent that no instructions are received from a Beneficiary with respect
to the Exchange Right, the Trustee shall not exercise or permit the exercise of the Exchange Right.

5.4 Purchase Price

The purchase price payable by PureRay Holdings for each Exchangeable Share to be purchased by
PureRay Holdings under the Exchange Right shall be an amount per share equal to: (i) the Current
Market Price of an PureRay U.S. Common Share on the last Business Day before the day of closing of
the purchase and sale of such Exchangeable Share under the Exchange Right, which shall be satisfied
in full by PureRay Holdings causing to be sent to such holder one PureRay U.S. Common Share, plus
(ii) to the extent not paid by the Corporation, an additional amount equivalent to the full amount
of all declared and unpaid dividends on each such Exchangeable Share held by such holder on any
dividend record date which occurred before the closing of the purchase and sale. The purchase
price for each such Exchangeable Share so purchased may be satisfied only by PureRay Holdings
delivering or causing to be delivered to the relevant Beneficiary one PureRay U.S. Common Share and
on the applicable payment date a cheque for the balance, if any, of the purchase price without
interest (but less any amounts withheld pursuant to section 5.12).

5.5 Exercise Instructions

Subject to the terms and conditions herein set forth, a Beneficiary shall be entitled, upon the
occurrence and during the continuance of an Insolvency Event, to instruct the Trustee to exercise
the Exchange Right with respect to all or any part of the Exchangeable Shares registered in the
name of such Beneficiary on the books of the Corporation. To cause the exercise of the Exchange
Right by the Trustee, the Beneficiary shall deliver to the Trustee, in person or by certified or
registered mail, at the Trustee’s office at Suite 600, 3625 Cumberland Blvd., Atlanta, Georgia,
30339 or at such other place as the Trustee may from time to time designate by written notice to
the Beneficiaries, the certificates representing the Exchangeable Shares which such Beneficiary
desires PureRay Holdings to purchase, duly endorsed in blank for transfer, and accompanied by such
other documents and instruments as may be required to effect a transfer of Exchangeable Shares
under the Canada Business Corporations Act and the by-laws of

 

- 11 -

the Corporation and such additional documents and instruments as the Trustee may reasonably
require, together with:

	 	(a)	 	a duly completed form of notice of exercise of the Exchange Right, contained on
the reverse of or attached to the Exchangeable Share certificates, stating: (i) that
the Beneficiary thereby instructs the Trustee to exercise the Exchange Right so as to
require PureRay Holdings to purchase from the Beneficiary the number of Exchangeable
Shares specified therein, (ii) that such Beneficiary has good title to and owns all
such Exchangeable Shares to be acquired by PureRay Holdings free and clear of all
liens, claims and encumbrances, (iii) the names in which the certificates representing
PureRay U.S. Common Shares issuable in connection with the exercise of the Exchange
Right are to be issued, and (iv) the names and addresses of the persons to whom such
new certificates should be delivered; and
	 
	 	(b)	 	payment (or evidence of payment satisfactory to the Trustee, the Corporation,
PureRay U.S. and PureRay Holdings) of the taxes (if any) payable as contemplated by
section 5.8 of this Agreement.

If only a part of the Exchangeable Shares represented by any certificate or certificates delivered
to the Trustee are to be purchased by PureRay Holdings under the Exchange Right, a new certificate
for the balance of such Exchangeable Shares shall be issued to the holder at the expense of the
Corporation.

5.6 Delivery of PureRay U.S. Common Shares; Effect of Exercise

Promptly after receipt of the certificates representing the Exchangeable Shares which the
Beneficiary desires PureRay Holdings to purchase under the Exchange Right, together with such
documents and instruments of transfer and a duly completed form of notice of exercise of the
Exchange Right (and payment of taxes, if any, payable as contemplated by section 5.8 or evidence
thereof), duly endorsed in blank, the Trustee shall notify PureRay U.S., PureRay Holdings and the
Corporation of its receipt of the same, which notice to PureRay U.S., PureRay Holdings and the
Corporation shall constitute exercise of the Exchange Right by the Trustee on behalf of the holder
of such Exchangeable Shares, and PureRay Holdings shall promptly thereafter deliver or cause to be
delivered to the Beneficiary of such Exchangeable Shares (or to such other persons, if any,
properly designated by such Beneficiary) the number of PureRay U.S. Common Shares issuable in
connection with the exercise of the Exchange Right, and on the applicable payment date cheques for
the balance, if any, of the total purchase price therefor without interest (but less any amounts
withheld pursuant to section 5.12); provided, however, that no such delivery shall be made unless
and until the Beneficiary requesting the same shall have paid (or provided evidence of payment
satisfactory to the Trustee, the Corporation, PureRay Holdings and PureRay U.S.) the taxes (if any)
payable as contemplated by section 5.8 of this Agreement. Immediately upon the giving of notice by
the Trustee to PureRay U.S., PureRay Holdings and the Corporation of the exercise of the Exchange
Right as provided in this section 5.6, the closing of the transaction of purchase and sale
contemplated by the Exchange Right shall be deemed to have occurred and the holder of such
Exchangeable Shares shall be deemed to have transferred to PureRay U.S. all of such holder’s right,
title and interest in and to such Exchangeable Shares and the related interest in the Trust Estate
and shall cease to be a holder of such Exchangeable Shares and shall not be entitled to exercise
any of the rights of a holder in respect thereof, other than the right to receive his, her or its
proportionate part of the total purchase price therefor, unless the requisite number of PureRay
U.S. Common Shares is not allotted, issued and delivered by PureRay Holdings to the Beneficiary
within five Business Days of the date of the giving of such notice by the Trustee, in which case
the rights of the Beneficiary shall remain unaffected until such PureRay U.S. Common Shares are so
allotted, issued and delivered by PureRay Holdings. Concurrently with such Beneficiary ceasing to
be a holder of Exchangeable Shares, the Beneficiary shall

 

- 12 -

be considered and deemed for all purposes to be the holder of the PureRay U.S. Common Shares
delivered to it pursuant to the Exchange Right.

5.7 Exercise of Exchange Right Subsequent to Retraction

In the event that a Beneficiary has exercised its right under section 5 of the Share Provisions to
require the Corporation to redeem any or all of the Exchangeable Shares held by the Beneficiary
(the “Retracted Shares”) and is notified by the Corporation pursuant to section 5.7 of the Share
Provisions that the Corporation will not be permitted as a result of solvency requirements of
applicable law to redeem all such Retracted Shares, and provided that PureRay Holdings shall not
have exercised the Retraction Call Right with respect to the Retracted Shares and that the
Beneficiary has not revoked the retraction request delivered by the Beneficiary to the Corporation
pursuant to section 5.1 of the Share Provisions, the retraction request will constitute and will be
deemed to constitute notice from the Beneficiary to the Trustee instructing the Trustee to exercise
the Exchange Right with respect to those Retracted Shares that the Corporation is unable to redeem.
In any such event, the Corporation hereby agrees with the Trustee and in favour of the Beneficiary
promptly to forward or cause to be forwarded to the Trustee all relevant materials delivered by the
Beneficiary to the Corporation or to the transfer agent of the Exchangeable Shares (including
without limitation, a copy of the retraction request delivered pursuant to section 5.1 of the Share
Provisions) in connection with such proposed redemption of the Retracted Shares and the Trustee
will thereupon exercise the Exchange Right with respect to the Retracted Shares that the
Corporation is not permitted to redeem and will require PureRay Holdings to purchase such shares in
accordance with the provisions of this Article 5.

5.8 Stamp or Other Transfer Taxes

Upon any sale of Exchangeable Shares to PureRay Holdings pursuant to the Exchange Right or the
Automatic Exchange Rights, the share certificate or certificates representing PureRay U.S. Common
Shares to be delivered in connection with the payment of the total purchase price therefor shall be
issued in the name of the Beneficiary of the Exchangeable Shares so sold or in such names as such
Beneficiary may otherwise direct in writing without charge to the holder of the Exchangeable Shares
so sold; provided, however, that such Beneficiary: (i) shall pay (and none of PureRay U.S., PureRay
Holdings, the Corporation or the Trustee shall be required to pay) any documentary, stamp, transfer
or other taxes that may be payable in respect of any transfer involved in the issuance or delivery
of such shares to a person other than such Beneficiary, or (ii) shall have evidenced to the
satisfaction of the Trustee, PureRay U.S., PureRay Holdings and the Corporation that such taxes, if
any, have been paid.

5.9 Notice of Insolvency Event

As soon as practicable following the occurrence of an Insolvency Event or any event that with the
giving of notice or the passage of time or both would be an Insolvency Event, the Corporation and
PureRay U.S. shall mail to the Trustee and each Beneficiary, at the expense of PureRay U.S., a
notice of such Insolvency Event, which notice shall contain a brief statement of the rights of the
Beneficiaries with respect to the Exchange Right.

5.10 PureRay U.S. Common Shares

PureRay U.S. hereby represents, warrants and covenants that the PureRay U.S. Common Shares issuable
as described herein will be duly authorized and validly issued as fully paid and nonassessable and
shall be free and clear of any lien, claim or encumbrance.

 

- 13 -

5.11 Automatic Exchange on Liquidation of PureRay U.S.

	(a)	 	PureRay U.S. will give the Trustee and each of the Beneficiaries notice of each of the
following events at the time set forth below:

	 	(i)	 	in the event of any determination by the board of directors of PureRay U.S. to
institute voluntary liquidation, dissolution or winding-up proceedings with respect to
PureRay U.S. or to effect any other distribution of assets of PureRay U.S. among its
shareholders for the purpose of winding up its affairs, at least 60 days before the
proposed effective date of such liquidation, dissolution, winding-up or other
distribution; and
	 
	 	(ii)	 	as soon as practicable following the earlier of receipt by PureRay U.S. of
notice of and PureRay U.S. otherwise becoming aware of any threatened or instituted
claim, suit, petition or other proceedings with respect to the involuntary liquidation,
dissolution or winding-up of PureRay U.S. or to effect any other distribution of assets
of PureRay U.S. among its shareholders for the purpose of winding up its affairs, in
each case where PureRay U.S. has failed to contest in good faith any such proceeding
commenced in respect of PureRay U.S. within 30 days of becoming aware thereof.

	 	 	Such notice shall include a brief description of the automatic exchange of Exchangeable
Shares for PureRay U.S. Common Shares provided for in section 5.11(c).
	 
	(b)	 	Any event contemplated by section 5.11(a)(i) or 5.11(a)(ii) above is referred to herein as a
“Liquidation Event”.
	 
	(c)	 	In order that the Beneficiaries will be able to participate on a pro rata basis with the
holders of PureRay U.S. Common Shares in the distribution of assets of PureRay U.S. in
connection with a Liquidation Event, on the fifth Business Day before the effective date (the
“Liquidation Event Effective Date”) of a Liquidation Event all of the then outstanding
Exchangeable Shares shall be automatically exchanged for PureRay U.S. Common Shares. To
effect such automatic exchange, PureRay Holdings shall purchase on the fifth Business Day
before the Liquidation Event Effective Date each Exchangeable Share then outstanding and held
by Beneficiaries, and each Beneficiary shall sell the Exchangeable Shares held by it at such
time, for a purchase price per share equal to: (i) the Current Market Price of a PureRay U.S.
Common Share on the fifth Business Day before the Liquidation Event Effective Date, which
shall be satisfied in full by PureRay Holdings causing to be alloted to the Beneficiary one
PureRay U.S. Common Share, and (ii) to the extent not paid by the Corporation, an additional
amount equivalent to the full amount of all declared and unpaid dividends on each such
Exchangeable Share held by such holder on any dividend record date which occurred before the
date of the exchange.
	 
	(d)	 	On the fifth Business Day before the Liquidation Event Effective Date, the closing of the
transaction of purchase and sale contemplated by the automatic exchange of Exchangeable Shares
for PureRay U.S. Common Shares shall be deemed to have occurred, and each Beneficiary shall be
deemed to have transferred to PureRay Holdings all of the Beneficiary’s right, title and
interest in and to such Beneficiary’s Exchangeable Shares and the related interest in the
Trust Estate and shall cease to be a holder of such Exchangeable Shares and PureRay Holdings
shall deliver to the Beneficiary the PureRay U.S. Common Shares issuable upon the automatic
exchange of Exchangeable Shares for PureRay U.S. Common Shares and on the applicable payment
date shall deliver to the Beneficiary a cheque for the balance, if any, of the total purchase
price for such Exchangeable Shares without interest but less any amounts withheld pursuant to
section 5.12. Concurrently with such Beneficiary ceasing to be a holder of Exchangeable
Shares, the

 

- 14 -

	 	 	Beneficiary shall be considered and deemed for all purposes to be the holder of the PureRay
U.S. Common Shares issued pursuant to the automatic exchange of Exchangeable Shares for
PureRay U.S. Common Shares and the certificates held by the Beneficiary previously
representing the Exchangeable Shares exchanged by the Beneficiary with PureRay Holdings
pursuant to such automatic exchange shall thereafter be deemed to represent PureRay U.S.
Common Shares issued to the Beneficiary by PureRay U.S. pursuant to such automatic exchange.
Upon the request of a Beneficiary and the surrender by the Beneficiary of Exchangeable
Share certificates deemed to represent PureRay U.S. Common Shares, duly endorsed in blank
and accompanied by such instruments of transfer as PureRay U.S. and PureRay Holdings may
reasonably require, PureRay Holdings shall deliver or cause to be delivered to the
Beneficiary certificates representing PureRay U.S. Common Shares of which the Beneficiary is
the holder.

5.12 Withholding Rights

Before the exchange or disposition of any Exchangeable Shares in accordance with this Article, each
Beneficiary shall deliver to the purchaser at or before such time:

	 	(a)	 	a certificate confirming that such Beneficiary is a resident of Canada for the
purposes of the ITA; or
	 
	 	(b)	 	in the case of a Beneficiary who is a non-resident of Canada for the purposes
of the ITA, a certificate satisfactory to the Corporation or PureRay Holdings, as the
case may be, acting reasonably, issued pursuant to subsection 116(2) or 116(4) of the
ITA (and any required certificate in respect of any similar provincial or governmental
tax laws), with respect to the exchangeable shares exchanged or disposed of, and in the
case of a certificate under 116(2) (and any required certificate in respect of any
similar provincial or governmental tax laws) having as the “certificate limit”, as
defined in subsection 116(2) of the ITA (or such provincial or governmental tax laws),
an amount no less than the cost to the purchaser of the exchangeable shares, as the
case may be; or
	 
	 	(c)	 	in the case of a Beneficiary who is a partnership, the Beneficiary shall also
provide, along with the documents referred to in clauses (a) and (b) above, a
certificate confirming the name and address of each member thereof and the percentage
of partnership interest held by each member (which partners and percentages are clearly
contemplated in the applicable certificate); or
	 
	 	(d)	 	if a Beneficiary fails to deliver one of the requisite certificates described
above, the Corporation or PureRay Holdings, as the case may be, shall be entitled to
deduct and withhold from any consideration otherwise payable to any such Beneficiary
such amounts as the purchaser is required or permitted to deduct and withhold with
respect to such payment under the ITA or any provision of provincial or governmental
tax law, in each case, as amended, consolidated or re-enacted from time to time,
provided that such withheld amount shall not be remitted before two business days
before the Remittance Date and where such certificate is delivered before the
Remittance Date, such amount shall be released to the Beneficiary. To the extent that
amounts are so withheld, such withheld amounts shall be treated for all purposes hereof
as having been paid to the Beneficiary in respect of which such deduction and
withholding was made, provided that such withheld amounts are actually remitted to the
appropriate taxing authority. To the extent that the amount so required or permitted
to be deducted or withheld from any payment to a Beneficiary exceeds the cash portion
of the consideration otherwise payable to the Beneficiary, the Corporation or PureRay
Holdings, as the case may be, as agent for

 

- 15 -

	 	 	 	the Beneficiary, shall sell or otherwise dispose of such portion of the
consideration as is necessary to provide sufficient funds to the Corporation or
PureRay Holdings, as the case may be, to enable it to comply with such deduction or
withholding requirement and the Corporation or PureRay Holdings, as the case may be,
shall notify the Beneficiary thereof and remit to such Beneficiary any unapplied
balance of the net proceeds of such sale. If the proceeds of such sale are
insufficient to fund the required withholding, such Beneficiary shall forthwith pay
to the Corporation or PureRay Holdings, as the case may be, or remit to the
applicable taxing authority the deficiency. The Beneficiary shall bear all
reasonable costs and expenses associated with any sale by the Corporation or PureRay
Holdings as the case may be, pursuant to the two immediately preceding sentences.

5.13 Other

At the option of PureRay U.S., the Exchange Right and the Automatic Exchange Rights may be
satisfied by PureRay U.S. PureRay U.S. hereby agrees that, in the event that PureRay Holdings is
for any reason unable to fulfill its obligations to purchase Exchangeable Shares in accordance with
the provisions of this Article 5, PureRay U.S. shall assume such obligations without any further
action on the part of the Trustee or the Beneficiaries.

ARTICLE 6

RESTRICTIONS ON ISSUE OF PURERAY U.S. SPECIAL VOTING STOCK

6.1 Issue of Additional Shares

During the term of this Agreement, PureRay U.S. will not, without the consent of the holders
at the relevant time of Exchangeable Shares, given in accordance with section 9 of the Share
Provisions, issue any shares of its Special Voting Stock in addition to the PureRay U.S. Special
Voting Shares.

ARTICLE 7

CONCERNING THE TRUSTEE

7.1 Powers and Duties of the Trustee

The rights, powers, duties and authorities of the Trustee under this Agreement, in its capacity as
Trustee of the Trust, shall include:

	 	(a)	 	receipt and deposit of the PureRay U.S. Special Voting Shares from PureRay U.S.
as Trustee for and on behalf of the Beneficiaries in accordance with the provisions of
this Agreement;
	 
	 	(b)	 	granting proxies to Beneficiaries as provided in this Agreement;
	 
	 	(c)	 	voting the Beneficiary Votes in accordance with the provisions of this
Agreement;
	 
	 	(d)	 	receiving the grant of the Exchange Right and the Automatic Exchange Rights
from PureRay Holdings as Trustee for and on behalf of the Beneficiaries in accordance
with the provisions of this Agreement;
	 
	 	(e)	 	exercising the Exchange Right and enforcing the benefit of the Automatic
Exchange Rights, in each case in accordance with the provisions of this Agreement, and
in

 

- 16 -

	 	 	 	connection therewith receiving from Beneficiaries Exchangeable Shares and other
requisite documents;
	 
	 	(f)	 	holding title to the Trust Estate;
	 
	 	(g)	 	investing any moneys forming, from time to time, a part of the Trust Estate as
provided in this Agreement;
	 
	 	(h)	 	taking action on its own initiative or at the direction of a Beneficiary or
Beneficiaries to enforce the obligations hereunder of each other party hereto; and
	 
	 	(i)	 	taking such other actions and doing such other things as are specifically
provided in this Agreement.

In the exercise of such rights, powers, duties and authorities the Trustee shall have (and is
granted) such incidental and additional rights, powers, duties and authority not in conflict with
any of the provisions of this Agreement as the Trustee, acting in good faith and in the reasonable
exercise of its discretion, may deem necessary, appropriate or desirable to effect the purpose of
the Trust. Any exercise of such discretionary rights, powers, duties and authorities by the
Trustee shall be final, conclusive and binding upon all persons. The Trustee in exercising its
rights, powers, duties and authorities hereunder shall act honestly and in good faith and with a
view to the best interests of the Beneficiaries and shall exercise the care, diligence and skill
that a reasonably prudent trustee would exercise in comparable circumstances.

7.2 No Conflict of Interest

The Trustee represents to each other party hereto that at the date of execution and delivery of
this Agreement there exists no material conflict of interest in the role of the Trustee as a
fiduciary hereunder and the role of the Trustee in any other capacity. The Trustee shall, within
90 days after it becomes aware that such material conflict of interest exists, either eliminate
such material conflict of interest or resign in the manner and with the effect specified in Article
10. If, notwithstanding the foregoing provisions of this section 7.2, the Trustee has such a
material conflict of interest, the validity and enforceability of this Agreement shall not be
affected in any manner whatsoever by reason only of the existence of such material conflict of
interest. If the Trustee contravenes the foregoing provisions of this section 7.2, any interested
party may apply to the Ontario Superior Court of Justice for an order that the Trustee be replaced
as Trustee hereunder.

7.3 Dealings with Transfer Agents, Registrars, etc.

PureRay U.S., PureRay Holdings and the Corporation irrevocably authorize the Trustee, from time to
time, to:

	 	(a)	 	consult, communicate and otherwise deal with the respective registrars and
transfer agents, and with any such subsequent registrar or transfer agent, of the
Exchangeable Shares and PureRay U.S. Common Shares; and
	 
	 	(b)	 	requisition, from time to time, from any such registrar or transfer agent any
information readily available from the records maintained by it which the Trustee may
reasonably require for the discharge of its duties and responsibilities under this
Agreement and PureRay U.S., PureRay Holdings and the Corporation irrevocably authorize
their respective registrars and transfer agents to comply with all such requests.

 

- 17 -

7.4 Books and Records

The Trustee shall keep available for inspection by PureRay U.S., PureRay Holdings and the
Corporation at the Trustee’s office in Atlanta, Georgia correct and complete books and records of
account relating to the Trust created by this Agreement, including without limitation, all relevant
data relating to instructions from Beneficiaries and all transactions pursuant to the Exchange
Right and the Automatic Exchange Rights.

7.5 Income Tax Returns and Reports

The Corporation shall, to the extent necessary, prepare and file on behalf of the Trust appropriate
United States and Canadian income tax returns and any other returns or reports as may be required
by applicable law or pursuant to the rules and regulations of any securities exchange or other
trading system through which the Exchangeable Shares may be traded.

7.6 Indemnification Before Certain Actions by Trustee

The Trustee shall exercise any or all of the rights, duties, powers or authorities vested in it by
this Agreement at the request, order or direction of any Beneficiary upon such Beneficiary
furnishing to the Trustee reasonable security or indemnity against the costs, expenses and
liabilities which may be incurred by the Trustee therein or thereby, provided that no Beneficiary
shall be obligated to furnish to the Trustee any such security or indemnity in connection with the
exercise by the Trustee of any of its rights, duties, powers and authorities with respect to the
PureRay U.S. Special Voting Shares pursuant to Article 4, subject to section 7.14, and with respect
to the Exchange Right pursuant to Article 5, subject to section 7.14, and with respect to the
Automatic Exchange Rights pursuant to Article 5. None of the provisions contained in this Agreement
shall require the Trustee to expend or risk its own funds or otherwise incur financial liability in
the exercise of any of its rights, powers, duties, or authorities unless funded, given security and
indemnified as aforesaid.

7.7 Action of Beneficiaries

No Beneficiary shall have the right to institute any action, suit or proceeding or to exercise any
other remedy authorized by this Agreement for the purpose of enforcing any of its rights or for the
execution of any trust or power hereunder unless the Beneficiary has requested the Trustee to take
or institute such action, suit or proceeding and furnished the Trustee with the security or
indemnity referred to in section 7.6 and the Trustee shall have failed to act within a reasonable
time thereafter. In such case, but not otherwise, the Beneficiary shall be entitled to take
proceedings in any court of competent jurisdiction such as the Trustee might have taken; it being
understood and intended that no one or more Beneficiaries shall have any right in any manner
whatsoever to affect, disturb or prejudice the rights hereby created by any such action, or to
enforce any right hereunder or the Voting Rights, the Exchange Rights or the Automatic Exchange
Rights except subject to the conditions and in the manner herein provided, and that all powers and
trusts hereunder shall be exercised and all proceedings at law shall be instituted, had and
maintained by the Trustee, except only as herein provided, and in any event for the equal benefit
of all Beneficiaries.

7.8 Reliance Upon Declarations

The Trustee shall not be considered to be in contravention of any its rights, powers, duties and
authorities hereunder if, when required, it acts and relies in good faith upon statutory
declarations, certificates, opinions or reports furnished pursuant to the provisions hereof or
required by the Trustee to be furnished to it in the exercise of its rights, powers, duties and
authorities hereunder if such statutory declarations,

 

- 18 -

certificates, opinions or reports comply with the provisions of section 7.9, if applicable, and
with any other applicable provisions of this trust agreement.

7.9 Evidence and Authority to Trustee

PureRay U.S., PureRay Holdings and the Corporation shall furnish to the Trustee evidence of
compliance with the conditions provided for in this Agreement relating to any action or step
required or permitted to be taken by PureRay U.S., PureRay Holdings, the Corporation or the Trustee
under this Agreement or as a result of any obligation imposed under this Agreement, including,
without limitation, in respect of the Voting Rights or the Exchange Right or the Automatic Exchange
Rights and the taking of any other action to be taken by the Trustee at the request of or on the
application of PureRay U.S., PureRay Holdings or the Corporation promptly if and when:

	 	(a)	 	such evidence is required by any other section of this Agreement to be
furnished to the Trustee in accordance with the terms of this section 7.9; or
	 
	 	(b)	 	the Trustee, in the exercise of its rights, powers, duties and authorities
under this Agreement, gives PureRay U.S., PureRay Holdings or the Corporation written
notice requiring it to furnish such evidence in relation to any particular action or
obligation specified in such notice.

Such evidence shall consist of an Officer’s Certificate of PureRay U.S., PureRay Holdings or the
Corporation or a statutory declaration or a certificate made by persons entitled to sign an
Officer’s Certificate stating that any such condition has been complied with in accordance with the
terms of this Agreement. Whenever such evidence relates to a matter other than the Voting Rights
or the Exchange Right or the Automatic Exchange Rights or the taking of any other action to be
taken by the Trustee at the request or on the application of PureRay U.S., PureRay Holdings or the
Corporation, and except as otherwise specifically provided herein, such evidence may consist of a
report or opinion of any solicitor, attorney, auditor, accountant, appraiser, valuer, engineer or
other expert or any other person whose qualifications give authority to a statement made by him,
her or it provided that if such report or opinion is furnished by a director, officer or employee
of PureRay U.S., PureRay Holdings or the Corporation it shall be in the form of an Officer’s
Certificate or a statutory declaration. Each statutory declaration, Officer’s Certificate, opinion
or report furnished to the Trustee as evidence of compliance with a condition provided for in this
trust agreement shall include a statement by the person giving the evidence:

	 	(a)	 	declaring that he, she or it has read and understands the provisions of this
Agreement relating to the condition in question;
	 
	 	(b)	 	describing the nature and scope of the examination or investigation upon which
he, she or it based the statutory declaration, certificate, statement or opinion; and
	 
	 	(c)	 	declaring that he, she or it has made such examination or investigation as he,
she or it believes is necessary to enable him, her or it to make the statements or give
the opinions contained or expressed therein.

7.10 Experts, Advisers and Agents

The Trustee may:

	 	(a)	 	in relation to these presents, act and rely on the opinion or advice of or
information obtained from any solicitor, attorney, auditor, accountant, appraiser,
valuer, engineer or

 

- 19 -

	 	 	 	other expert, whether retained by the Trustee or by PureRay U.S., PureRay Holdings
or the Corporation or otherwise, and may employ such assistants as may be necessary
to the proper discharge of its powers and duties and determination of its rights
hereunder and may pay proper and reasonable compensation for all such legal and
other advice or assistance as aforesaid; and
	 
	 	(b)	 	employ such agents and other assistants as it may reasonably require for the
proper discharge of its powers and duties hereunder, and may pay reasonable
remuneration for all services performed for it (and shall be entitled to receive
reasonable remuneration for all services performed by it) in the discharge of the
trusts hereof and compensation for all disbursements, costs and expenses made or
incurred by it in the discharge of its duties hereunder and in the management of the
Trust.

7.11 Investment of Moneys Held by Trustee

Unless otherwise provided in this Agreement, any moneys held by or on behalf of the Trustee which
under the terms of this Agreement may or ought to be invested or which may be on deposit with the
Trustee or which may be in the hands of the Trustee may be invested and reinvested in the name or
under the control of the Trustee in securities in which, under the laws of the Province of Ontario,
trustees are authorized to invest trust moneys, provided that such securities are stated to mature
within two years after purchase by the Trustee, and the Trustee shall so invest such moneys on the
written direction of the Corporation. Pending the investment of any moneys as hereinbefore
provided, such moneys may be deposited in the name of the Trustee in any chartered bank in Canada
or, with the consent of the Corporation, in the deposit department of the Trustee or any other loan
or trust company authorized to accept deposits under the laws of Canada or any province thereof at
the rate of interest then current on similar deposits.

7.12 Trustee Not Required to Give Security

The Trustee shall not be required to give any bond or security in respect of the execution of the
trusts, rights, duties, powers and authorities of this trust agreement or otherwise in respect of
the premises.

7.13 Trustee Not Bound to Act on Request

Except as otherwise specifically provided in this Agreement, the Trustee shall not be bound to act
in accordance with any direction or request of PureRay U.S., PureRay Holdings or the Corporation or
of the directors thereof until a duly authenticated copy of the instrument or resolution containing
such direction or request shall have been delivered to the Trustee, and the Trustee shall be
empowered to act upon any such copy purporting to be authenticated and believed by the Trustee to
be genuine.

7.14 Conflicting Claims

If conflicting claims or demands are made or asserted with respect to any interest of any
Beneficiary in any Exchangeable Shares, including any disagreement between the heirs,
representatives, successors or assigns succeeding to all or any part of the interest of any
Beneficiary in any Exchangeable Shares, resulting in conflicting claims or demands being made in
connection with such interest, then the Trustee shall be entitled, at its sole discretion, to
refuse to recognize or to comply with any such claims or demands. In so refusing, the Trustee may
elect not to exercise any Voting Rights, Exchange Rights or Automatic Exchange Rights subject to
such conflicting claims or demands and, in so doing, the Trustee shall not be or become liable to
any person on account of such election or its failure or refusal to comply

 

- 20 -

with any such conflicting claims or demands. The Trustee shall be entitled to continue to refrain
from acting and to refuse to act until:

	 	(a)	 	the rights of all adverse claimants with respect to the Voting Rights, Exchange
Right or Automatic Exchange Rights subject to such conflicting claims or demands have
been adjudicated by a final judgment of a court of competent jurisdiction; or
	 
	 	(b)	 	all differences with respect to the Voting Rights, Exchange Right or Automatic
Exchange Rights subject to such conflicting claims or demands have been conclusively
settled by a valid written agreement binding on all such adverse claimants, and the
Trustee shall have been furnished with an executed copy of such agreement certified to
be in full force and effect.

If the Trustee elects to recognize any claim or comply with any demand made by any such adverse
claimant, it may in its discretion require such claimant to furnish such surety bond or other
security satisfactory to the Trustee as it shall deem appropriate to fully indemnify it as between
all conflicting claims or demands.

7.15 Acceptance of Trust

The Trustee hereby accepts the Trust created and provided for by and in this Agreement and agrees
to perform the same upon the terms and conditions herein set forth and to hold all rights,
privileges and benefits conferred hereby and by law in trust for the various persons who shall from
time to time be Beneficiaries, subject to all the terms and conditions herein set forth.

ARTICLE 8

COMPENSATION

8.1 Fees and Expenses of the Trustee

PureRay U.S. and the Corporation jointly and severally agree to pay the Trustee reasonable
compensation for all of the services rendered by it under this Agreement and will reimburse the
Trustee for all reasonable expenses (including taxes other than taxes based on the net income of
the Trustee) and disbursements, including the cost and expense of any suit or litigation of any
character and any proceedings before any governmental agency reasonably incurred by the Trustee in
connection with its duties under this Agreement; provided that PureRay U.S. and the Corporation
shall have no obligation to reimburse the Trustee for any expenses or disbursements paid, incurred
or suffered by the Trustee in any suit or litigation in which the Trustee is determined to have
acted in bad faith or with gross negligence or wilful misconduct.

ARTICLE 9

INDEMNIFICATION AND LIMITATION OF LIABILITY

9.1 Indemnification of the Trustee

PureRay U.S. and the Corporation jointly and severally agree to indemnify and hold harmless the
Trustee and each of its partners, officers and agents appointed and acting in accordance with this
Agreement (collectively, the “Indemnified Parties”) against all claims, losses, damages, reasonable
costs, penalties, fines and reasonable expenses (including reasonable expenses of the Trustee’s
legal counsel) which, without fraud, negligence, recklessness, wilful misconduct or bad faith on
the part of such Indemnified Party, may be paid, incurred or suffered by the Indemnified Party by
reason or as a result of the Trustee’s

 

- 21 -

acceptance or administration of the Trust, its compliance with its duties set forth in this
Agreement, or any written or oral instruction delivered to the Trustee by PureRay U.S. or the
Corporation pursuant hereto. In no case shall PureRay U.S. or the Corporation be liable under this
indemnity for any claim against any of the Indemnified Parties unless PureRay U.S. and the
Corporation shall be notified by the Trustee of the written assertion of a claim or of any action
commenced against the Indemnified Parties, promptly after any of the Indemnified Parties shall have
received any such written assertion of a claim or shall have been served with a summons or other
first legal process giving information as to the nature and basis of the claim. Subject to (ii)
below, PureRay U.S. and the Corporation shall be entitled to participate at their own expense in
the defence and, if PureRay U.S. and the Corporation so elect at any time after receipt of such
notice, either of them may assume the defence of any suit brought to enforce any such claim. The
Trustee shall have the right to employ separate counsel in any such suit and participate in the
defence thereof but the fees and expenses of such counsel shall be at the expense of the Trustee
unless: (i) the employment of such counsel has been authorized by PureRay U.S. or the Corporation;
or (ii) the named parties to any such suit include both the Trustee and PureRay U.S. or the
Corporation and the Trustee shall have been advised by counsel acceptable to PureRay U.S. or the
Corporation, acting reasonably, that there may be one or more legal defences available to the
Trustee that are different from or in addition to those available to PureRay U.S. or the
Corporation and that, in the judgment of such counsel, would present a conflict of interest were a
joint representation to be undertaken (in which case PureRay U.S. and the Corporation shall not
have the right to assume the defence of such suit on behalf of the Trustee but shall be liable to
pay the reasonable fees and expenses of counsel for the Trustee).

9.2 Limitation of Liability

The Trustee shall not be held liable for any loss which may occur by reason of depreciation of the
value of any part of the Trust Estate or any loss incurred on any investment of funds pursuant to
this Agreement, except to the extent that such loss is attributable to the fraud, gross negligence,
wilful misconduct or bad faith on the part of the Trustee.

ARTICLE 10

CHANGE OF TRUSTEE

10.1 Resignation

The Trustee, or any trustee hereafter appointed, may at any time resign by giving written notice of
such resignation to PureRay U.S. and the Corporation specifying the date on which it desires to
resign, provided that such notice shall not be given less than one month before such desired
resignation date unless PureRay U.S. and the Corporation otherwise agree and provided further that
such resignation shall not take effect until the date of the appointment of a successor trustee and
the acceptance of such appointment by the successor trustee. Upon receiving such notice of
resignation, PureRay U.S. and the Corporation shall promptly appoint a successor trustee by written
instrument in duplicate, one copy of which shall be delivered to the resigning trustee and one copy
to the successor trustee.

10.2 Removal

The Trustee, or any trustee hereafter appointed, may (provided a successor trustee is appointed) be
removed at any time on not less than 30 days’ prior notice by written instrument executed by
PureRay U.S. and the Corporation, in duplicate, one copy of which shall be delivered to the trustee
so removed and one copy to the successor trustee.

 

- 22 -

10.3 Successor Trustee

Any successor trustee appointed as provided under this Agreement shall execute, acknowledge and
deliver to PureRay U.S., PureRay Holdings and the Corporation and to its predecessor trustee an
instrument accepting such appointment. Thereupon the resignation or removal of the predecessor
trustee shall become effective and such successor trustee, without any further act, deed or
conveyance, shall become vested with all the rights, powers, duties and obligations of its
predecessor under this Agreement, with the like effect as if originally named as trustee in this
Agreement. However, on the written request of PureRay U.S., PureRay Holdings and the Corporation
or of the successor trustee, the trustee ceasing to act shall, upon payment of any amounts then due
it pursuant to the provisions of this Agreement, execute and deliver an instrument transferring to
such successor trustee all the rights and powers of the trustee so ceasing to act. Upon the
request of any such successor trustee, PureRay U.S., PureRay Holdings, the Corporation and such
predecessor trustee shall execute any and all instruments in writing for more fully and certainly
vesting in and confirming to such successor trustee all such rights and powers.

10.4 Notice of Successor Trustee

Upon acceptance of appointment by a successor trustee as provided herein, PureRay U.S., PureRay
Holdings and the Corporation shall cause to be mailed notice of the succession of such trustee
hereunder to each Beneficiary specified in a List. If PureRay U.S. or the Corporation shall fail
to cause such notice to be mailed within 10 days after acceptance of appointment by the successor
trustee, the successor trustee shall cause such notice to be mailed at the expense of PureRay U.S.
and the Corporation.

ARTICLE 11

U.S. SUCCESSORS

11.1 Certain Requirements In Respect of Combination, etc.

PureRay U.S. shall not, directly or indirectly, consummate any transaction (whether by way of
reconstruction, reorganization, consolidation, merger, transfer, sale, lease or otherwise) whereby
all or substantially all of its undertaking, property and assets would become the property of any
other person or, in the case of a merger, of the continuing corporation resulting therefrom unless,
but may do so if:

	 	(a)	 	such other person or continuing corporation (herein called the “PureRay U.S.
Successor”), by operation of law, becomes, without more, bound by the terms and
provisions of this Agreement or, if not so bound, executes, before or contemporaneously
with the consummation of such transaction, an agreement supplemental hereto and such
other instruments (if any) as are satisfactory to the Trustee, acting reasonably, and
in the opinion of legal counsel to the Trustee are reasonably necessary or advisable to
evidence the assumption by the PureRay U.S. Successor of liability for all moneys
payable and property deliverable hereunder and the covenant of such PureRay U.S.
Successor to pay and deliver or cause to be delivered the same and its agreement to
observe and perform all the covenants and obligations of PureRay U.S. under this
Agreement; and
	 
	 	(b)	 	such transaction shall, to the satisfaction of the Trustee, acting reasonably,
and in the opinion of legal counsel to the Trustee, be upon such terms and conditions
as substantially to preserve and not to impair in any material respect any of the
rights, duties, powers and authorities of the Trustee or of the Beneficiaries
hereunder.

 

- 23 -

11.2 Vesting of Powers in Successor

Whenever the conditions of section 11.1 have been duly observed and performed, the Trustee and, if
required by section 11.1, PureRay U.S. Successor and the parties hereto shall execute and deliver
the supplemental agreement provided for in Article 12 and thereupon PureRay U.S. Successor shall
possess and from time to time may exercise each and every right and power of PureRay U.S. under
this Agreement in the name of PureRay U.S. or otherwise and any act or proceeding by any provision
of this Agreement required to be done or performed by the board of directors of PureRay U.S. or any
officers of PureRay U.S. may be done and performed with like force and effect by the directors or
officers of such PureRay U.S. Successor.

11.3 Wholly-Owned Subsidiaries

Nothing herein shall be construed as preventing the amalgamation or merger of any wholly-owned
direct or indirect subsidiary of PureRay U.S. with or into PureRay U.S. or the winding-up,
liquidation or dissolution of any wholly-owned subsidiary of PureRay U.S. provided that all of the
assets of such subsidiary are transferred to PureRay U.S. or another wholly-owned direct or
indirect subsidiary of PureRay U.S. and any such transactions are expressly permitted by this
Article 11.

ARTICLE 12

AMENDMENTS AND SUPPLEMENTAL TRUST AGREEMENTS

12.1 Amendments, Modifications, etc.

This Agreement may not be amended or modified except by an agreement in writing executed by PureRay
U.S., PureRay Holdings, the Corporation and the Trustee and approved by the Beneficiaries in
accordance with section 9 of the Share Provisions.

12.2 Ministerial Amendments

Notwithstanding the provisions of section 12.1, the parties agreement may in writing, at any
time and from time to time, without the approval of the Beneficiaries, amend or modify this trust
agreement for the purposes of:

	 	(a)	 	adding to the covenants of any or all parties hereto for the protection of the
Beneficiaries hereunder provided that the Board of Directors and the board of directors
of PureRay U.S. shall be of the good faith opinion that such additions will not be
prejudicial to the rights or interests of the Beneficiaries;
	 
	 	(b)	 	making such amendments or modifications not inconsistent with this Agreement as
may be necessary or desirable with respect to matters or questions which, in the good
faith opinion of the Board of Directors and the board of directors of PureRay U.S. and
in the opinion of the Trustee, having in mind the best interests of the Beneficiaries
it may be expedient to make, provided that such boards of directors and the Trustee
shall be of the opinion that such amendments and modifications will not be prejudicial
to the interests of the Beneficiaries; or
	 
	 	(c)	 	making such changes or corrections which, on the advice of counsel to PureRay
U.S., the Corporation and the Trustee, are required for the purpose of curing or
correcting any ambiguity or defect or inconsistent provision or clerical omission or
mistake or manifest error, provided that the Trustee, the Board of Directors and the
board of directors of

 

- 24 -

	 	 	 	PureRay U.S. shall be of the opinion that such changes or corrections will not be
prejudicial to the rights and interests of the Beneficiaries.

12.3 Meeting to Consider Amendments

The Corporation, at the request of PureRay U.S., shall call a meeting or meetings of the
Beneficiaries for the purpose of considering any proposed amendment or modification requiring
approval pursuant hereto. Any such meeting or meetings shall be called and held in accordance with
the by-laws of the Corporation, the Share Provisions and all applicable laws.

12.4 Changes in Capital of PureRay U.S. and the Corporation

At all times after the occurrence of any event contemplated pursuant to section 2.6 of the Support
Agreement or otherwise, as a result of which either PureRay U.S. Common Shares or the Exchangeable
Shares or both are in any way changed, this Agreement shall forthwith be amended and modified as
necessary in order that it shall apply with full force and effect, mutatis mutandis, to all new
securities into which PureRay U.S. Common Shares or the Exchangeable Shares or both are so changed
and the parties hereto shall execute and deliver a supplemental agreement giving effect to and
evidencing such necessary amendments and modifications.

12.5 Execution of Supplemental Trust Agreements

From time to time the Corporation, PureRay U.S., PureRay Holdings and the Trustee may, subject to
the provisions of these presents, and they shall, when so directed by these presents, execute and
deliver by their proper officers, agreements or other instruments supplemental hereto, which
thereafter shall form part hereof, for any one or more of the following purposes:

	 	(a)	 	evidencing the succession of PureRay U.S. Successors and the covenants of and
obligations assumed by each such PureRay U.S. Successor in accordance with the
provisions of Article 11 and the successors of any successor trustee in accordance with
the provisions of Article 10;
	 
	 	(b)	 	making any additions to, deletions from or alterations of the provisions of
this Agreement or the Voting Rights, the Exchange Right or the Automatic Exchange
Rights which, in the opinion of the Trustee, will not be prejudicial to the interests
of the Beneficiaries or are, in the opinion of counsel to the Trustee, necessary or
advisable in order to incorporate, reflect or comply with any legislation the
provisions of which apply to PureRay U.S., PureRay Holdings, the Corporation, the
Trustee or this Agreement; and
	 
	 	(c)	 	for any other purposes not inconsistent with the provisions of this Agreement,
including without limitation, to make or evidence any amendment or modification to this
Agreement as contemplated hereby, provided that, in the opinion of the Trustee, the
rights of the Trustee and Beneficiaries will not be prejudiced thereby.

ARTICLE 13

TERMINATION

13.1 Term

The Trust created by this Agreement shall continue until the earliest to occur of the following
events:

 

- 25 -

	 	(a)	 	no outstanding Exchangeable Shares are held by a Beneficiary;
	 
	 	(b)	 	each of PureRay U.S. and the Corporation elects in writing to terminate the
trust and such termination is approved by the Beneficiaries in accordance with section
9 of the Share Provisions; and
	 
	 	(c)	 	21 years from the date of this Agreement.

13.2 Survival of Agreement

This Agreement shall survive any termination of the Trust and shall continue until there are no
Exchangeable Shares outstanding held by a Beneficiary; provided, however, that the provisions of
Articles 8 and 9 shall survive any such termination of this Agreement.

ARTICLE 14

GENERAL

14.1 Severability

If any provision of this Agreement is held to be invalid, illegal or unenforceable, the validity,
legality or enforceability of the remainder of this Agreement shall not in any way be affected or
impaired thereby and the agreement shall be carried out as nearly as possible in accordance with
its original terms and conditions.

14.2 Enurement

This Agreement shall be binding upon and enure to the benefit of the parties hereto and their
respective successors and permitted assigns and to the benefit of the Beneficiaries.

14.3 Notices to Parties

All notices and other communications between the parties hereunder shall be in writing and shall be
deemed to have been given if delivered personally or by confirmed telecopy to the parties at the
following addresses (or at such other address for such party as shall be specified in like notice):

	 	(a)	 	If to PureRay U.S., the Corporation or PureRay Holdings to it at:
	 
	 	 	 	3625 Cumberland Blvd

Suite 600

Atlanta, GA 30339

	 
	 	 	 	Attention:      President

Facsimile:      678-202-8911

 

- 26 -

	 	(b)	 	If to the Trustee to:
	 
	 	 	 	Derek Blackburn

1388 River Road

Manotick, ON

K4M 1B4
	 
	 	 	 	Facsimile: 888-366-9627

Any notice or other communication given personally shall be deemed to have been given and received
upon delivery thereof and if given by telecopy shall be deemed to have been given and received on
the date of receipt thereof unless such day is not a Business Day in which case it shall be deemed
to have been given and received upon the immediately following Business Day.

14.4 Notice to Beneficiaries

Any and all notices to be given and any documents to be sent to any Beneficiaries may be given or
sent to the address of such Beneficiary shown on the register of holders of Exchangeable Shares in
any manner permitted by the by-laws of the Corporation from time to time in force in respect of
notices to shareholders and shall be deemed to be received (if given or sent in such manner) at the
time specified in such by-laws, the provisions of which by-laws shall apply mutatis mutandis to
notices or documents as aforesaid sent to such Beneficiaries.

14.5 Counterparts

This Agreement may be executed in counterparts, each of which shall be deemed an original, but all
of which taken together shall constitute one and the same instrument.

14.6 Governing Law

This Agreement shall be construed and enforced in accordance with the laws of the Province of
Ontario and the laws of Canada applicable therein without regard to principles of conflicts of law.

14.7 Attornment

Any action or proceeding arising out of or relating to this Agreement may be instituted in the
courts of Ontario, and each party hereby waives any objection which it may have now or hereafter to
the venue of any such action or proceeding and irrevocably submits to the jurisdiction of the said
courts in any such action or proceeding, agrees to be bound by any final judgment of the said
courts and not to seek, and hereby waives, any review of the merits of any such judgment by the
courts of any other jurisdiction and hereby appoints the Corporation at its registered office in
the Province of Ontario as attorney for service of process.

[INTENTIONALLY BLANK — SIGNATURE PAGE FOLLOWS]

 

- 27 -

IN WITNESS WHEREOF the parties hereto have caused this Agreement to be duly executed as of the date
first above written.

	 	 	 	 	 
	 	NORTH AMERICAN NATURAL GAS, INC.

 	 
	 	By:  	/s/ Jim Glavas
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	PURERAY HOLDINGS INC.

 	 
	 	By:  	/s/ Jim Glavas
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	PURERAY ACQUISITION INC.

 	 
	 	By:  	/s/ Jim Glavas
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

	 	 	 	 	 	 	 
	SIGNED, SEALED AND DELIVERED

	 	 	)	 	 	 
	In the presence of:

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	 

	 	 	)	 	 	/s/ Derek Blackburn
	 

	 	 	 	 	 	 
	Witness (signature)

	 	 	)	 	 	Derek Blackburn
	 

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	 
	 	 	 	 	 	 
	Witness Name (please print)

	 	 	)exv10w3

EXHIBIT 10.3

SUPPORT AGREEMENT

THIS AGREEMENT is made the 24th day of July, 2008,

B E T W E E N:

NORTH AMERICAN NATURAL GAS, INC., a corporation existing under the laws of the State
of Washington,

(hereinafter referred to as “PureRay U.S.”),

- and -

PURERAY HOLDINGS ULC, an unlimited liability corporation formed under the laws of
the Province of Alberta,

(hereinafter referred to as “PureRay Holdings”),

- and -

PURERAY ACQUISITION INC., a corporation formed under the laws of Canada,

(hereinafter referred to as the “Corporation”)

WHEREAS:

	A.	 	the Corporation is a wholly-owned subsidiary of PureRay Holdings and PureRay Holdings is a
wholly-owned subsidiary of PureRay U.S.;
	 
	B.	 	pursuant to a share purchase agreement dated July 24, 2008 (the “Purchase Agreement”),
between PureRay U.S., PureRay Holdings, the Corporation and all of the shareholders of PureRay
Corporation (“PureRay”), the Corporation has agreed to acquire all of the outstanding shares
in the capital of PureRay and, in satisfaction of payment of the purchase price therefor, to
issue one Exchangeable Share (as hereinafter defined) for each such share of PureRay acquired
by the Corporation;
	 
	C.	 	the articles of the Corporation set forth the rights, privileges, restrictions and conditions
(collectively, the “Exchangeable Share Provisions”) attaching to the Exchangeable Shares; and
	 
	D.	 	the parties desire to make appropriate provision and to establish a procedure whereby PureRay
U.S. and PureRay Holdings will take certain actions and make certain payments and deliveries
necessary to ensure that the Corporation will be able to make certain payments and to deliver
or cause to be delivered PureRay U.S. Common Shares in satisfaction of the obligations of the

 

- 2 - 

	 	 	Corporation under the Exchangeable Share Provisions with respect to the payment and
satisfaction of dividends, Liquidation Amounts, Retraction Prices and Redemption Prices, all
in accordance with the Exchangeable Share Provisions;

NOW THEREFORE in consideration of the respective covenants provided in this Agreement and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties agree as follows:

ARTICLE 1

DEFINITIONS AND INTERPRETATION

1.1 Defined Terms

Each term denoted herein by initial capital letters and not otherwise defined herein shall have the
meaning ascribed thereto in the Exchangeable Share Provisions.

1.2 Interpretation Not Affected by Headings, Etc.

The division of this Agreement into articles, sections and paragraphs and the insertion of headings
are for convenience of reference only and shall not affect the construction or interpretation of
this Agreement.

1.3 Number, Gender, Etc.

Words importing the singular number only shall include the plural and vice versa. Words importing
the use of any gender shall include the feminine and the masculine.

1.4 Date For Any Action

If any date on which any action is required to be taken under this Agreement is not a Business Day,
such action shall be required to be taken on the next succeeding Business Day.

ARTICLE 2

COVENANTS OF PURERAY U.S. AND THE CORPORATION

2.1 Covenants of PureRay U.S. Regarding Exchangeable Shares

So long as any Exchangeable Shares are outstanding, PureRay U.S. shall:

	 	(a)	 	not declare or pay any dividend on the PureRay U.S. Common Shares unless: (i)
the Corporation will have sufficient assets, funds and other property available to
enable the due declaration and the due and punctual payment, in accordance with
applicable law, of an equivalent dividend (as provided for in the Exchangeable Share
Provisions) on the Exchangeable Shares, and (ii) the Corporation shall simultaneously
declare or pay, as the case may be, an equivalent dividend on the Exchangeable Shares,
in each case in accordance with the Exchangeable Share Provisions;
	 
	 	(b)	 	cause the Corporation to declare simultaneously with the declaration of any
dividend on PureRay U.S. Common Shares an equivalent dividend on the Exchangeable
Shares and, when such dividend is paid on the PureRay U.S. Common Shares, cause the
Corporation to pay simultaneously therewith such equivalent dividend on the
Exchangeable Shares, in each case in accordance with the Exchangeable Share Provisions;

 

- 3 -

	 	(c)	 	advise the Corporation sufficiently in advance of the declaration by PureRay
U.S. of any dividend on the PureRay U.S. Common Shares and take all such other actions
as are necessary, in co-operation with the Corporation, to ensure that the respective
declaration date, record date and payment date for a dividend on the Exchangeable
Shares shall be the same as the record date, declaration date and payment date for the
corresponding dividend on the PureRay U.S. Common Shares and such dividend will
correspond with any requirement of the stock exchange on which the Exchangeable Shares
may be then listed;
	 
	 	(d)	 	ensure that the record date for any dividend declared on PureRay U.S. Common
Shares is not less than 10 days after the declaration date for such dividend;
	 
	 	(e)	 	take all such actions and do all such things as are necessary or desirable to
enable and permit the Corporation, in accordance with applicable law, to pay and
otherwise perform its obligations with respect to the satisfaction of the Liquidation
Amount, the Retraction Price or the Redemption Price in respect of each issued and
outstanding Exchangeable Share upon the liquidation, dissolution or winding-up of the
Corporation, the delivery of a Retraction Request by a holder of Exchangeable Shares or
a redemption of Exchangeable Shares by the Corporation, including, without limitation,
all such actions and all such things as are necessary or desirable to enable and permit
the Corporation to cause PureRay U.S. Common Shares to be allotted to the holders of
Exchangeable Shares in accordance with the provisions of sections 4, 5 or 6, as the
case may be, of the Exchangeable Share Provisions;
	 
	 	(f)	 	take all such actions and do all such things as are reasonably necessary or
desirable to enable and permit PureRay Holdings, in accordance with applicable law, to
perform its obligations arising upon the exercise by it of the Liquidation Call Right,
the Retraction Call Right or the Redemption Call Right, and further including, without
limitation, all such actions and all such things as are necessary or desirable to
enable and permit PureRay Holdings to cause PureRay U.S. Common Shares to be allotted
to the holders of Exchangeable Shares, in accordance with the provisions of the
Liquidation Call Right, the Retraction Call Right or the Redemption Call Right, as the
case may be; and
	 
	 	(g)	 	not exercise its vote as a shareholder, directly or indirectly, to initiate the
voluntary liquidation, dissolution or winding-up of the Corporation nor take any action
or omit to take, directly or indirectly, any action that is designed to result in the
liquidation, dissolution or winding-up of the Corporation.

2.2 Authorization of PureRay U.S. Common Shares

PureRay U.S. hereby represents, warrants and covenants for the benefit of the holders of the
Exchangeable Shares that it has irrevocably reserved for issuance and will at all times while any
Exchangeable Shares (other than Exchangeable Shares held by PureRay U.S. or its Affiliates) are
outstanding, keep available, free from preemptive rights out of its authorized and unissued capital
stock such number of PureRay U.S. Common Shares (or other shares or securities into which PureRay
U.S. Common Shares may be reclassified or changed as contemplated by Section 2.6 hereof): (i) as is
equal to the sum of (A) the number of Exchangeable Shares issued and outstanding from time to time
(other than those Exchangeable Shares that have been acquired by PureRay U.S. or an Affiliate of
PureRay U.S.), and (B) the number of Exchangeable Shares issuable upon the exercise of all rights
to acquire Exchangeable Shares outstanding from time to time; and (ii) as are now and may hereafter
be required to enable and permit the Corporation to meet its obligations hereunder, under the
Voting and Exchange Trust Agreement, under the Exchangeable Share Provisions and under any other
security or commitment

 

- 4 -

pursuant to which PureRay U.S. may now or hereafter be required to allot PureRay U.S. Common Shares
and to enable and permit PureRay Holdings to exercise and to meet its obligations under the
Liquidation Call Right, the Retraction Call Right and the Redemption Call Right.

2.3 Notification of Certain Events

In order to assist PureRay U.S. in complying with its obligations hereunder and to permit PureRay
Holdings to exercise the Liquidation Call Right, the Retraction Call Right and the Redemption Call
Right, the Corporation shall give PureRay U.S. and PureRay Holdings notice of each of the following
events at the time set forth below:

	 	(a)	 	in the event of any determination by the board of directors of the Corporation
(the “Board of Directors”) to institute voluntary liquidation, dissolution or winding
up proceedings with respect to the Corporation or to effect any other distribution of
the assets of the Corporation among its shareholders for the purpose of winding up its
affairs, at least 60 days prior to the proposed effective date of such liquidation,
dissolution, winding up or other distribution;
	 
	 	(b)	 	immediately, upon the earlier of receipt by the Corporation of notice of and
the Corporation otherwise becoming aware of any threatened or instituted claim, suit,
petition or other proceedings with respect to the involuntary liquidation, dissolution
or winding up of the Corporation or to effect any other distribution of the assets of
the Corporation among its shareholders for the purpose of winding up its affairs;
	 
	 	(c)	 	immediately, upon receipt by the Corporation of a Retraction Request;
	 
	 	(d)	 	on the same date on which notice of redemption is given to the holders of
Exchangeable Shares, upon the determination of a Redemption Date in accordance with the
Exchangeable Share Provisions; and
	 
	 	(e)	 	as soon as practicable upon the issuance by the Corporation of any Exchangeable
Shares or rights to acquire Exchangeable Shares (other than the issuance of
Exchangeable Shares pursuant to the Purchase Agreement).

2.4 Delivery of PureRay U.S. Common Shares

In furtherance of PureRay U.S.’s obligations under sections 2.1(e) and 2.1(f) hereof, upon notice
from the Corporation or PureRay Holdings of any event that requires any such party to cause PureRay
U.S. Common Shares to be delivered to any holder of Exchangeable Shares, PureRay U.S. shall
forthwith cause the requisite number of PureRay U.S. Common Shares to be allotted to the former
holder of the surrendered Exchangeable Shares, as the Corporation or PureRay Holdings shall direct.
All such PureRay U.S. Common Shares shall be duly issued as fully paid and non-assessable and
shall be free and clear of any lien, claim, encumbrance, security interest or adverse claim.

2.5 Qualification of PureRay U.S. Common Shares

PureRay U.S. covenants that if any PureRay U.S. Common Shares (or other shares or securities into
which PureRay U.S. Common Shares may be reclassified or changed as contemplated by section 2.6
hereof) to be issued and delivered hereunder, including for greater certainty, pursuant to the
Exchangeable Share Provisions, the Exchange Right or the Automatic Exchange Rights (as such terms
are defined in the Voting and Exchange Trust Agreement) require registration or qualification with
or approval of or the filing of any document including any prospectus or similar document or the
taking of any proceeding with

 

- 5 -

or the obtaining of any order, ruling or consent from any governmental or regulatory authority
under any Canadian or United States federal, state or provincial law or regulation or pursuant to
the rules and regulations of any regulatory authority or stock exchange or quotation system on
which outstanding PureRay U.S. Common Shares are listed, quoted or posted for trading or the
fulfilment of any other legal requirement in Canada or the United States (collectively, the
“Applicable Laws”) before such shares (or other shares or securities into which PureRay U.S. Common
Shares may be reclassified or changed as contemplated by section 2.6 hereof) may be issued and
delivered by PureRay U.S. to the initial holder thereof, PureRay U.S. will in good faith
expeditiously take all such actions and do all such things as are reasonably necessary to cause
such PureRay U.S. Common Shares (or other shares or securities into which PureRay U.S. Common
Shares may be reclassified or changed as contemplated by section 2.6 hereof) to be and remain duly
registered, qualified or approved. PureRay U.S. will in good faith expeditiously take all such
actions and do all such things as are necessary to cause all PureRay U.S. Common Shares (or other
shares or securities into which PureRay U.S. Common Shares may be reclassified or changed as
contemplated by section 2.6 hereof) to be delivered hereunder, including for greater certainty,
pursuant to the Exchangeable Share Provisions, the Exchange Right or the Automatic Exchange Rights
to be listed, quoted or posted for trading on all stock exchanges and quotation systems on which
such shares are listed, quoted or posted for trading at such time.

2.6 Economic Equivalence

	(a)	 	PureRay U.S. will not without the prior approval of the Corporation and the prior approval of
the holders of the Exchangeable Shares given in accordance with section 9 of the Exchangeable
Share Provisions:

	 	(i)	 	issue or distribute PureRay U.S. Common Shares (or securities exchangeable for
or convertible into or carrying rights to acquire PureRay U.S. Common Shares) to the
holders of all or substantially all of the then outstanding PureRay U.S. Common Shares
by way of stock dividend or other distribution, other than an issue of PureRay U.S.
Common Shares (or securities exchangeable for or convertible into or carrying rights to
acquire PureRay U.S. Common Shares) to holders of PureRay U.S. Common Shares who
exercise an option to receive dividends in PureRay U.S. Common Shares (or securities
exchangeable for or convertible into or carrying rights to acquire PureRay U.S. Common
Shares) in lieu of receiving cash dividends; or
	 
	 	(ii)	 	issue or distribute rights, options or warrants to the holders of all or
substantially all of the then outstanding PureRay U.S. Common Shares entitling them to
subscribe for or to purchase PureRay U.S. Common Shares (or securities exchangeable for
or convertible into or carrying rights to acquire PureRay U.S. Common Shares); or
	 
	 	(iii)	 	issue or distribute to the holders of all or substantially all of the then
outstanding PureRay U.S. Common Shares: (A) shares or securities of PureRay U.S. of any
class other than PureRay U.S. Common Shares (other than shares convertible into or
exchangeable for or carrying rights to acquire PureRay U.S. Common Shares), (B) rights,
options or warrants other than those referred to in section 2.6(a)(ii) above, (C)
evidences of indebtedness of PureRay U.S. or (D) assets of PureRay U.S.;

unless on a per share basis of such rights, options, securities, the economic equivalent on
a per share basis of such rights, options, securities, shares, evidences of indebtedness or
other assets to holders of the Exchangeable Shares is issued or distributed simultaneously
to holders of the Exchangeable Shares.

 

- 6 -

	(b)	 	PureRay U.S. will not, without the prior approval of the Corporation and the prior approval
of the holders of the Exchangeable Shares given in accordance with section 9 of the
Exchangeable Share Provisions:

	 	(i)	 	subdivide, redivide or change the then outstanding PureRay U.S. Common Shares
into a greater number of shares of PureRay U.S. Common Shares; or
	 
	 	(ii)	 	reduce, combine, consolidate or change the then outstanding PureRay U.S. Common
Shares into a lesser number of PureRay U.S. Common Shares; or
	 
	 	(iii)	 	reclassify or otherwise change the PureRay U.S. Common Shares or effect an
amalgamation, merger, reorganization or other transaction affecting the PureRay U.S.
Common Shares;

unless the same or an economically equivalent change to, or in the rights of holders of, the
Exchangeable Shares is simultaneously made to, or in the rights of the holders of, the
Exchangeable Shares.

	(c)	 	PureRay U.S. will ensure that the record date for any event referred to in section 2.6(a) or
2.6(b) above, or (if no record date is applicable for such event) the effective date for any
such event, is not less than 10 Business Days after the date on which such event is declared
or announced by PureRay U.S. (with simultaneous notice thereof to be given by PureRay U.S. to
the Corporation).
	 
	(d)	 	The Board of Directors shall determine, in good faith and in its sole discretion (with the
assistance of such reputable and qualified independent financial advisors and/or other experts
as the Board of Directors may require), economic equivalence for the purposes of any event
referred to in section 2.6(a) or 2.6(b) above and each such determination shall be conclusive
and binding on PureRay U.S. In making each such determination, the following factors shall,
without excluding other factors determined by the Board of Directors to be relevant, be
considered by the Board of Directors:

	 	(i)	 	in the case of any stock dividend or other distribution payable in PureRay U.S.
Common Shares, the number of such shares issued in proportion to the number of PureRay
U.S. Common Shares previously outstanding;
	 
	 	(ii)	 	in the case of the issuance or distribution of any rights, options or warrants
to subscribe for or purchase PureRay U.S. Common Shares (or securities exchangeable for
or convertible into or carrying rights to acquire PureRay U.S. Common Shares), the
relationship between the exercise price of each such right, option or warrant and the
current market value (as determined by the Board of Directors in the manner
contemplated below) of a PureRay U.S. Common Share;
	 
	 	(iii)	 	in the case of the issuance or distribution of any other form of property
(including without limitation any shares or securities of PureRay U.S. of any class
other than PureRay U.S. Common Shares, any rights, options or warrants other than those
referred to in section 2.6(d)(ii) above, any evidences of indebtedness of PureRay U.S.
or any assets of PureRay U.S.), the relationship between the fair market value (as
determined by the Board of Directors in the manner above contemplated) of such property
to be issued or distributed with respect to each outstanding PureRay U.S. Common Share
and the current market value (as determined by the Board of Directors in the manner
contemplated below) of a PureRay U.S. Common Share;

 

- 7 -

	 	(iv)	 	in the case of any subdivision, redivision or change of the then outstanding
PureRay U.S. Common Shares into a greater number of PureRay U.S. Common Shares or the
reduction, combination or consolidation or change of the then outstanding PureRay U.S.
Common Shares into a lesser number of PureRay U.S. Common Shares or any amalgamation,
merger, reorganization or other transaction affecting PureRay U.S. Common Shares, the
effect thereof upon the then outstanding PureRay U.S. Common Shares; and
	 
	 	(v)	 	in all such cases, the general taxation consequences of the relevant event to
holders of Exchangeable Shares to the extent that such consequences may differ from the
taxation consequences to holders of PureRay U.S. Common Shares as a result of
differences between taxation laws of Canada and the United States (except for any
differing consequences arising as a result of differing marginal taxation rates and
without regard to the individual circumstances of holders of Exchangeable Shares).

For purposes of the foregoing determinations, the current market value of any security
listed and traded or quoted on a securities exchange shall be the weighted average of the
daily prices of such security during a period of not less than 20 consecutive trading days
ending not more than three trading days before the date of determination on the principal
securities exchange on which such securities are listed and traded or quoted; provided,
however, that if the PureRay U.S. Common Shares are not then quoted on any stock exchange or
automated quotation system or if, in the opinion of the Board of Directors the public
distribution or trading activity of such securities during such period does not create a
market that reflects the fair market value of such securities, then the current market value
thereof shall be determined by the Board of Directors, in good faith and in its sole
discretion (with the assistance of such reputable and qualified independent financial
advisors and/or other experts as the board may require), and provided further that any such
determination by the board shall be conclusive and binding on PureRay U.S.

	(e)	 	PureRay Holdings and the Corporation agree that, to the extent required, upon due notice from
PureRay U.S., PureRay Holdings and the Corporation will use their best efforts to take or
cause to be taken such steps as may be necessary for the purposes of ensuring that appropriate
dividends are paid or other distributions are made by the Corporation, or subdivisions,
re-divisions or changes are made to the Exchangeable Shares, in order to implement the
required economic equivalence with respect to the PureRay U.S. Common Shares and Exchangeable
Shares as provided for in this section 2.6.

2.7 Tender Offers, Etc.

In the event that a merger, consolidation or tender offer, share exchange offer, issuer bid,
take-over bid or similar transaction with respect to PureRay U.S. Common Shares (an “Offer”) is
proposed by PureRay U.S. or is proposed to PureRay U.S. or its shareholders and is recommended by
the board of directors of PureRay U.S., or is otherwise effected or to be effected with the consent
or approval of the board of directors of PureRay U.S. and the Exchangeable Shares are not redeemed
by the Corporation or purchased by PureRay Holdings (or PureRay U.S.) pursuant to the Redemption
Call Right, PureRay U.S. will use its reasonable efforts expeditiously and in good faith to take
all such actions and do all such things as are necessary or desirable to enable and permit holders
of Exchangeable Shares to participate in such Offer to the same extent and on an economically
equivalent basis as the holders of PureRay U.S. Common Shares, without discrimination. Without
limiting the generality of the foregoing, PureRay U.S. will use its reasonable efforts
expeditiously and in good faith to ensure that holders of Exchangeable Shares may participate in
all such Offers without being required to retract Exchangeable Shares as against the Corporation
(or, if so required, to ensure that any such retraction shall be effective only upon, and shall be
conditional upon, the closing of the Offer and only to the extent necessary to tender or deposit to
the Offer). Nothing herein shall affect the rights of the Corporation to redeem (or PureRay
Holdings or

 

- 8 -

PureRay U.S.) to purchase pursuant to the Redemption Call Right, Exchangeable Shares, as
applicable, in the event of a PureRay U.S. Control Transaction.

2.8 PureRay U.S. and Affiliates Not to Vote Exchangeable Shares

PureRay U.S. covenants and agrees that it will appoint and cause to be appointed proxy holders with
respect to all Exchangeable Shares held by PureRay U.S. and its Affiliates for the sole purpose of
attending each meeting of holders of Exchangeable Shares in order to be counted as part of the
quorum for each such meeting. PureRay U.S. further covenants and agrees that it will not, and will
cause its Affiliates not to, exercise any voting rights that may be exercisable by holders of
Exchangeable Shares from time to time pursuant to the Exchangeable Share Provisions or pursuant to
the provisions of the Canada Business Corporations Act (or any successor or other corporate statute
by which the Corporation may in the future be governed) with respect to any Exchangeable Shares
held by it or by its Affiliates in respect of any matter considered at any meeting of holders of
Exchangeable Shares.

2.9 Ownership of Outstanding Shares

Without the prior approval of the Corporation and the prior approval of the holders of Exchangeable
Shares given in accordance with section 9 of the Exchangeable Share Provisions, PureRay U.S.
covenants and agrees in favour of the Corporation that, as long as any outstanding Exchangeable
Shares are owned by any person or entity other than PureRay U.S. or any of its Affiliates, PureRay
U.S. will be and remain the direct or indirect beneficial owner of all issued and outstanding
voting shares in the capital of the Corporation and PureRay Holdings.

ARTICLE 3

PURERAY U.S. SUCCESSORS

3.1 Certain Requirements in Respect of Combination, Etc.

PureRay U.S., directly or indirectly, shall not consummate any transaction (whether by way of
reconstruction, reorganization, consolidation, merger, transfer, sale, lease or otherwise) whereby
all or substantially all of its undertaking, property and assets would become the property of any
other person or, in the case of a merger, of the continuing corporation resulting therefrom unless,
but may do so if:

 

- 9 -

	 	(a)	 	such other person or continuing corporation (the “PureRay U.S. Successor”) by
operation of law, becomes, without more, bound by the terms and provisions of this
Agreement or, if not so bound, executes, prior to or contemporaneously with the
consummation of such transaction, an agreement supplemental hereto and such other
instruments (if any) as are reasonably necessary or advisable to evidence the
assumption by the PureRay U.S. Successor of liability for all moneys payable and
property deliverable by PureRay U.S. hereunder and the covenant of such PureRay U.S.
Successor to pay and deliver or cause to be paid and delivered the same and its
agreement to observe and perform all the covenants and obligations of PureRay U.S.
under this Agreement; and
	 
	 	(ii)	 	such transaction shall be upon such terms and conditions so as to substantially
preserve and not impair in any material respect the rights, interests, duties, powers
and authorities of the other parties hereunder or the holders of Exchangeable Shares.

3.2 Vesting of Powers in PureRay U.S. Successor

Whenever the conditions of section 3.1 have been duly observed and performed, the PureRay U.S.
Successor and the parties hereto, if required by section 3.1, shall execute and deliver a
supplemental agreement hereto and thereupon PureRay U.S. Successor shall possess and from time to
time may exercise each and every right and power of PureRay U.S. under this Agreement in the name
of PureRay U.S. or otherwise and any act or proceeding by any provision of this Agreement required
to be done or performed by the board of directors of PureRay U.S. or any officers of PureRay U.S.
may be done and performed with like force and effect by the directors or officers of such PureRay
U.S. Successor.

3.3 Wholly-Owned Subsidiaries

Nothing herein shall be construed as preventing the amalgamation, merger, or other combination of
any wholly-owned direct or indirect subsidiary of PureRay U.S. with or into PureRay U.S. or the
winding-up, liquidation or dissolution of any wholly-owned subsidiary of PureRay U.S. provided that
all of the assets of such subsidiary are transferred to, and all obligations of such subsidiary are
assumed by, PureRay U.S. or another wholly-owned direct or indirect subsidiary of PureRay U.S., and
any such transactions are expressly permitted by this Article 3.

ARTICLE 4

GENERAL

4.1 Term

This Agreement shall come into force and be effective as of the date hereof and shall terminate and
be of no further force and effect at such time as no Exchangeable Shares (or securities or rights
convertible into or exchangeable for or carrying rights to acquire Exchangeable Shares) are held by
any party other than PureRay U.S. and any of its Affiliates.

4.2 Changes in Capital of PureRay U.S. and the Corporation

Notwithstanding the provisions of section 4.4 hereof, at all times after the occurrence of any
event effected pursuant to section 2.6 or 2.7 hereof or otherwise, as a result of which either the
PureRay U.S. Common Shares or the Exchangeable Shares or both are in any way changed, this
Agreement shall forthwith be amended and modified as necessary in order that it shall apply with
full force and effect, mutatis mutandis, to all new securities into which PureRay U.S. Common
Shares or the Exchangeable

 

- 10 -

Shares or both are so changed and the parties hereto shall execute and deliver an agreement in
writing giving effect to and evidencing such necessary amendments and modifications.

4.3 Severability

If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced
by any rule or law, or public policy, all other conditions and provisions of this Agreement shall
nevertheless remain in full force and effect so long as the economic or legal substance of the
transactions contemplated hereby is not affected in any manner materially adverse to any party.
Upon such determination that any term or other provision is invalid, illegal or incapable of being
enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect
the original intent of the parties as closely as possible in an acceptable manner to the end that
the transactions contemplated hereby are fulfilled to the fullest extent possible.

4.4 Amendments, Modifications, Etc.

This Agreement may not be amended or modified except by an agreement in writing executed by the
Corporation, PureRay U.S. and PureRay Holdings and approved by the holders of the Exchangeable
Shares in accordance with section 9 of the Exchangeable Share Provisions.

4.5 Administrative Amendments

Notwithstanding the provisions of section 4.4, the parties to this Agreement may in writing, at any
time and from time to time, without the approval of the holders of the Exchangeable Shares, amend
or modify this Agreement for the purposes of: (i) adding to the covenants of any or all parties
provided that in the good faith opinion of the Board of Directors and the board of directors of
PureRay U.S. such additions will not be prejudicial to the rights or interests of the holders of
the Exchangeable Shares; (ii) making such amendments or modifications not inconsistent with this
Agreement as may be necessary or desirable with respect to matters or questions which, in the good
faith opinion of the Board of Directors and the board of directors of PureRay U.S., it may be
expedient to make, provided that each such board of directors shall be of the good faith opinion
that such amendments or modifications will not be prejudicial to the interests of the holders of
the Exchangeable Shares; or (iii) making such changes or corrections which, on the written advice
of counsel to the Corporation and PureRay U.S., are required for the purpose of curing or
correcting any ambiguity or defect or inconsistent provision or clerical omission or mistake or
manifest error, provided that in the good faith opinion of the Board of Directors and the board of
directors of PureRay U.S. such changes or corrections will not be prejudicial to the interests of
the holders of the Exchangeable Shares.

4.6 Meeting to Consider Amendments

The Corporation, at the request of PureRay U.S., shall call a meeting or meetings of the holders of
the Exchangeable Shares for the purpose of considering any proposed amendment or modification
requiring approval pursuant to section 4.4 hereof. Any such meeting or meetings shall be called
and held in accordance with the by-laws of the Corporation, the Exchangeable Share Provisions and
all applicable laws.

4.7 Enurement

This Agreement shall be binding upon and enure to the benefit of the parties hereto, the holders of
the Exchangeable Shares and their respective successors and permitted assigns, as well as to their
respective heirs, executors, trustees, administrators and other personal representatives.

 

- 11 -

4.8 Notices to Parties

All notices and other communications between the parties shall be in writing and shall be deemed to
have been given if delivered personally or by overnight courier service, transmitted by facsimile
or mailed by registered or certified mail, postage prepaid to the parties at the following
addresses (or at such other address for either such party as shall be specified in like notice):

If to PureRay U.S., the Corporation or PureRay Holdings to it at:

3625 Cumberland Blvd

Suite 600

Atlanta, GA 30339

Attention:            President

Facsimile:           678-202-8911

Any notice or other communication given in accordance herewith shall be deemed to have been given
and received upon receipt thereof unless such day is not a Business Day in which case it shall be
deemed to have been given and received upon the immediately following Business Day.

4.9 Counterparts

This Agreement may be executed in counterparts, each of which shall be deemed an original, and all
of which taken together shall constitute one and the same instrument.

4.10 Governing Law

This Agreement shall be construed and enforced in accordance with the laws of the Province of
Ontario and the laws of Canada applicable therein without regard to principles of conflicts of
laws.

4.11 Attornment

Any action or proceeding arising out of or relating to this Agreement may be instituted in the
courts of Ontario, and each party hereby waives any objection which it may have now or hereafter to
the venue of any such action or proceeding, irrevocably submits to the jurisdiction of the said
courts in any such action or proceeding, agrees to be bound by any judgment of the said courts and
not to seek, and hereby waives, any review of the merits of any such judgment by the courts of any
other jurisdiction and each party (other than the Corporation) hereby appoints the Corporation at
its registered office in the province of Ontario as such party’s attorney for service of process.

[INTENTIONALLY BLANK – SIGNATURE PAGE FOLLOWS]

 

- 12 -

IN WITNESS WHEREOF the parties hereto have caused this Agreement to be duly executed as of the date
first above written.

	 	 	 	 	 
	 	NORTH AMERICAN NATURAL GAS, INC.

 	 
	 	By:  	/s/ Jim Glavas
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	PURERAY HOLDINGS ULC

 	 
	 	By:  	/s/ Jim Glavas
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	PURERAY ACQUISITION INC.

 	 
	 	By:  	/s/ Jim Glavas
 	 
	 	 	Name:  	 	 
	 	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]